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Alcohol use disorder is one of the most prevalent mental health disorders 
worldwide, treatment options are limited, and relapse rates are high. There remains an 
urgent need for effective treatments. Research involving the therapeutic potential of 
classic hallucinogens has reemerged in recent decades and the hallucinogen psilocybin 
has shown some promise in early studies. We aim to assess the efficacy of psilocybin in 
treating alcohol use disorder with a 10-week double blind randomized double 
dummy crossover control trial comparing psilocybin-assisted psychotherapy to 
ketamine-assisted psychotherapy in individuals with alcohol use disorder. Our 
primary outcome will be the mean percent heavy drinking days in the four-week periods 
following drug administration sessions among participants in both treatment groups. We 
hope that our results will provide further evidence for the therapeutic role of psilocybin in 
addiction and that our study design may serve as a model for future randomized 
controlled trials of psychedelics.  
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Chapter 1 – Introduction 
1.1 Background Information and Rationale 
Alcohol use disorder (AUD) is one of the most prevalent mental health disorders 
worldwide and the third leading preventable cause of death in the United States.1 The 
National Institute on Alcohol Abuse and Alcoholism (NIAAA) defines AUD as a chronic 
relapsing brain disease characterized by an impaired ability to stop or control alcohol use 
despite adverse social, occupational, or health consequences.2  In the Diagnostic and 
Statistical Manual of Mental Disorders, 5th edition (DSM-V), AUD comprises both 
alcohol abuse and alcohol dependence disorders; it is further subclassified into mild, 
moderate, or severe.3  
AUD exacts a heavy social, economic, and medical burden in the United States 
and globally. The World Health Organization (WHO) estimates that in 2012 the 12-
month and lifetime prevalence of AUD ranged from 13.9 to 29.1% of the global 
population.4 In the U.S., an estimated 16 million people had AUD in 2015.5 AUD is a 
significant contributor to global morbidity and mortality.  In 2012, an estimated 3.3 
million deaths, or 5.9% of all global deaths, were attributable to alcohol consumption. 
The WHO ranks alcohol use as the eighth leading risk factor for death worldwide; in the 
U.S., alcohol misuse is the third leading cause of death. AUD also has severe negative 
effects on one’s productivity, interpersonal and psychological functioning, as well as 
one’s short- and long-term health.4 Chronic excessive alcohol use can damage every 
organ in the body and contributes to over 200 diseases and injury-related health 
conditions, including liver cirrhosis, cancers, and dementia.1 These consequences come at 
an economic cost including lost productivity and increased health care dollars. In 2006, it 
is estimated that the economic cost of excessive drinking in the U.S. was $223.5 billion6.  
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Despite a high societal cost of AUD, treatment options are few and relapse rates 
are high, even when treatment methods are combined.7,8 Common treatment options for 
AUD are pharmacological interventions, behavioral therapy, and mutual support groups. 
The FDA has approved only three drugs for AUD:  Naltrexone, Acamprosate, and 
Disulfiram, and these medications display poor efficacy, low adherence rates, or adverse 
effects at a population level.5 Empirically-validated behavioral interventions include 
cognitive behavioral therapy, motivational interviewing, and marital and family 
counseling. Mutual support treatment groups include Alcoholics Anonymous and other 
12-step programs. Due in part to the low efficacy rates of available treatments (and other 
factors such as the stigma attached to this disease), the majority of people with AUD in 
the U.S. go untreated. According to the NIAAA, based on data from 2001-2002, only 
14.6% of people with AUD ever receive treatment.9 There remains substantial room for 
the development of effective treatment alternatives and classic hallucinogens, particularly 
psilocybin, have shown promise in early studies.   
Classic hallucinogens exert their primary effects through agonist activity at 
serotonin 2A (5-HT2A) receptors, and include lysergic acid diethylamide (LSD), 
dimethyltryptamine (DMT), psilocybin, and mescaline. 10-12  These hallucinogens have 
significant perceptual, cognitive, affective, and somatosensory changes, such as visual 
and auditory hallucinations, difficulty thinking, mood disturbances and dissociative 
phenomena.13 Interest in the therapeutic use of classic hallucinogens to treat addiction 
and other mental health diseases originated in the 1950s, shortly after Albert Hoffman 
discovered the psychoactive effects of LSD and recognized its therapeutic potential.14 
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Over the subsequent 20 years until their scheduling by the US government as controlled 
substances, psychedelic research expanded rapidly.  
The earliest investigations began with Humphry Osmond and Abram Hoffer’s 
work in Saskatchewan in the early 1950s, which emerged from clinical observations 
suggesting that some alcohol dependent patients who had experienced delirium tremens 
(a severe form of alcohol withdrawal that involves sudden and severe mental or nervous 
system changes) subsequently decreased their drinking.15 They hypothesized that this 
hallucinatory state was therapeutic and, therefore, LSD might reduce drinking by 
inducing a delirium tremens-like state.  At the conclusion of their work Osmund and 
Hoffer ended up parting from their original hypothesis instead proposing that the 
observed efficacy of LSD in their subjects was attributed to the drug’s ability to induce 
deep introspection and insight, which made subjects more amenable to 
psychotherapy.14,16,17  
This led to numerous hypothesis-generating studies exploring the ideas put forth 
by Humphry and Osmund. Researchers observed that relatively high doses of 
psychedelics induce a “peak-psychedelic” or mystical experience of ego loss 
(characterized by profound alterations in perception, mood, volition, cognition, and self-
experience), which impacts long-term behavior, personality and cognition.18,19 
Furthermore, researchers found that when combined with psychotherapy, hallucinogens 
facilitated the psychotherapeutic process and strengthened the therapeutic 
relationship.14,20 Several studies on alcohol dependence found improvements in self-
acceptance and interpersonal relationships, as well as reductions in craving and alcohol 
use, among subjects treated with LSD.18,21,22 
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1.2 Problem Statement  
While the work done during the 1950s to early 1970s generated substantial 
support for the therapeutic role of psychedelics in addiction, much of the research done 
during that time period had significant methodological limitations; most notably, a lack 
of randomized, double-blind, placebo-controlled trials.16,18 Further, the randomized 
clinical trials that did exist did not preserve the blind (i.e. the hallucinogen under 
investigation was compared to an inactive substance or a non-hallucinogen such as 
amphetamine). Thus, the patients in the studies always knew when they were getting 
hallucinogen or the presumed inactive comparator. When psychedelic research resumed 
in the 1990s, researchers expanded upon the earlier work of their colleagues, refining 
treatment models of psychedelic therapy and establishing specific guidelines for the 
adequate study of treatment effectiveness of psychedelics.16,23 By the beginning of the 
21st century, psychedelic research was again undergoing rapid growth.  
In this new era of psychedelic research, major advances have been made towards 
understanding the acute effects of psychedelics on physiology, cognition, emotion, and 
brain function.24 Numerous studies have demonstrated the safety of these drugs when 
administered in a controlled clinical setting. 24-26 Recent addiction research has shifted its 
focus from LSD to psilocybin as a potential adjunct for treatment because psilocybin 
works through the same mechanism of action, but is shorter-acting and overall, better 
tolerated.27 Several lines of evidence suggest that psilocybin has clinically relevant 
effects in the treatment of addiction. Recently completed proof-of-concept studies of 
psilocybin in conjunction with psychotherapy for nicotine and alcohol dependence 
demonstrated that the intervention led to substantial decreases in use of the target 
substance28,29 This proof-of-concept study of psilocybin for AUD was the first to ever test 
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this relationship28. Currently, Phase 2 randomized-controlled trials (RCTs) are underway 
to test the efficacy of psilocybin-assisted treatment of tobacco, alcohol, and cocaine use 
disorders. Given the current plethora of evidence in support of psilocybin as a useful 
pharmacological tool for treatment of AUD and the dearth of RCTs investigating this 
hypothesis, further investigation is warranted. 
1.3 Goal and Objectives 
This study aims to further clarify whether psychedelic-assisted treatment with 
psilocybin of AUD is clinically useful. Specifically, this study aims to: (1) characterize 
the acute effects of psilocybin in alcoholic patients (2) evaluate the effect of psilocybin 
treatment on drinking outcomes relative to a ketamine control. 
1.4 Hypothesis 
Psilocybin administered in conjunction with targeted psychotherapy will lead to a 
greater clinically significant reduction in the mean percent heavy drinking days compared 
to active placebo ketamine among individuals with alcohol use disorder.  
1.5 Definitions 
Mean percent heavy drinking days: mean days during which participants consume five or 
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Chapter 2 – Review of the Literature 
2.1 Introduction – Literature Search Criteria 
A thorough review of the literature was conducted from December, 2018 to April, 
2019 using Ovid (Medline), PubMed, Embase, and Cochrane Medical Library using a 
concept table (Appendix A). Searches included clinical trials, randomized control trials, 
systematic reviews, and meta-analyses. All publications that used hallucinogens as a 
therapy for addiction were selected for further review. Additional publications relevant to 
this study were obtained through forward searches and hand searches, and included in the 
review.  
2.2 Overview of Current Treatments for AUD 
AUD is a heterogenous disease with a wide range of phenotypes, and individual 
response to treatments varies greatly. Accordingly, current interventions for AUD 
integrate pharmacological treatment with psychosocial therapy to target the genetic, 
psychological and environmental factors that are believed to interact to cause this 
disorder. Goals of treatment include: achieving abstinence; reducing the frequency and 
severity of relapse, and improving both health and psychosocial functioning.  
2.2.1 Approved Medications for AUD 
Disulfiram was the first medication to become approved by the FDA for the 
treatment of AUD. It is prescribed as an anti-craving medication to abstinent individuals 
with a high motivation to stay sober, since it works by inhibiting the metabolism of 
alcohol which induces severe adverse reactions if alcohol is ingested. While disulfiram 
has been found to act as a deterrent to alcohol ingestion in a controlled environment, its 
efficacy drops significantly in an unsupervised environment.1 As a result, in “real world” 
RCTs, adherence rates were low and disulfiram did not show efficacy.2 A meta-analysis 
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of open-label trials and RCTs of disulfiram use in alcoholics found that overall, compared 
to controls, disulfiram showed a higher success rate, with Hedge’s g = 0.58 (95% CI = 
0.35-0.82). However, only open-label trials showed significant superiority over controls 
(g = 0.70, 95% CI = 0.46-0.93). Disulfiram was also found to be more effective than the 
control condition when compared to naltrexone (g = 0.77, 95% CI = 0.52-1.02) and to 
acamprosate (g = 0.76, 95% CI = 0.4-1.48)3. While the rate of disulfiram prescription 
continues to climb in some parts of the world, overall disulfiram prescription rates are 
dropping as its role in treatment is generally displaced by more recently introduced 
medications.4 
Naltrexone is a non-selective opiate antagonist that targets and blocks the 
rewarding neurobiological effect of alcohol.1,5,6 It is prescribed as an adjunct to 
psychosocial intervention for reducing heavy drinking in alcohol dependent individuals 
and prolonging abstinence.1,7 Trajectory-based studies of naltrexone suggest that it is 
most effective in patients who have a high likelihood of drinking heavily on a regular 
basis during treatment and that it is ineffective in patients who drink sporadically during 
treatment.8,9 A 2013 meta-analysis of RCTs of naltrexone for alcohol dependence found a 
small but significant effect of Naltrexone compared to placebo on the outcome of heavy 
drinking (g = 0.189, CI 0.123-0.255, p < 0.001).10  
Acamprosate is an analogue of GABA and is thought to act as a functional 
glutamate antagonist, dampening glutaminergic hyperactivity associated with alcohol 
withdrawal.11,12 Results on the efficacy of Acamprosate are mixed. A meta-analysis of 
RCTs comparing acamprosate to naltrexone for alcohol dependence found a small but 
significant effect of Acamprosate compared to placebo on the outcome of heavy drinking 
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that was similar to that of Naltrexone (g = 0.359, CI 0.246-0.472, p < 0.001).10 However, 
it did not show efficacy on its primary endpoints in either of the large RCTs conducted in 
the U.S. including NIAAA Project COMBINE, the largest pharmacotherapy study in the 
history of the field.13,14 
2.2.2 Evidence-Based Psychosocial Interventions 
Psychosocial interventions are psychologically-based interventions that aim to 
reduce consumption behavior or alcohol-related problems.15 The most commonly used 
interventions are motivational interviewing (MI), cognitive-behavioral therapy (CBT), 
brief interventions, and Twelve-step facilitation programs (TSF).16 Clinical trials have 
found no superiority of one behavioral treatment over another.1 These interventions have 
shown moderate efficacy in reducing drinking and maintaining abstinence, and not all 
individuals benefit from psychosocial therapy. 
The psychosocial intervention proposed in this study is motivational enhancement 
therapy (MET), which is a type of MI, and a common intervention for the treatment of 
AUD; it is one of the few treatments designed specifically for abstinence initiation17. 
MET consists of a patient-centered therapy that aims to produce rapid internally-
motivated changes by exploring and resolving ambivalence towards behavior.18 A 
systematic review of RCTs published between 1997 and 2007 assessing the beneficial or 
detrimental effects of motivational techniques in the treatment of alcohol dependence 
found that MET was significantly more effective than a minimal intervention control at 
reducing heavy alcohol use when assessed at five-month follow-up (moderate effect 
size).18 Additionally, MET was favored over control in individuals who drank 
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excessively and frequently at six-month follow-up (large effect size). The analyses 
showed a trend favoring MI with relapse prevention over control (p = 0.07).18  
2.3 Promise of Psilocybin-Assisted Psychotherapy for AUD 
2.3.1 Clinical Studies of Classic Hallucinogens in Substance Use Disorders 
The main focus of research during the 1950s-1970s in the field of addiction was 
the use of LSD for the treatment of alcoholism. Following the success of Drs. Hoffer and 
Osmond, administration of LSD with psychotherapy to alcoholic patients became an 
accepted clinical treatment in Saskatchewan and the subject of many studies. The 
majority of these studies had significant methodological flaws, including an absence of 
adequate control groups; substantial variation in dose quantity and duration; a lack of 
control for confounding factors; non-standardized criteria for therapeutic outcome; and 
diverse theoretical approaches for assessing beneficial effects.19,20 In a recent meta-
analysis of these studies, about a dozen were reported to have some form of control 
group, only six were randomized trials (N = 536), and of these, five were fully double-
blind.21 All of these studies employed a single high-dose LSD session and controls that 
included inactive placebo, low-dose LSD (50 mcg), ephedrine, and amphetamine. At the 
post-treatment follow-up (which ranged from one to 12 months), the odds ratio for 
improvement was 1.96 (95% confidence interval [1.36-2.84], Z = 3.59, p = 0.0003). 
Among the five studies reporting dichotomous outcomes, 59% of the LSD-treated 
participants were significantly improved vs. 38% of the control participants (pooled 
benefit difference 16%, 95% confidence interval 8%-25%, p = 0.0003, number needed to 
treat = 6). All six studies demonstrated robust treatment effects, which remained 
significant at six months follow-up.19,21  Despite their methodological flaws, these studies 
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provide persuasive preliminary evidence for the efficacy of 5-HT2A receptor agonists in 
the treatment of alcoholism.  
Clinical research on psilocybin for the treatment of addictions is still in its early 
stages. To date, there are only two completed studies to explore the efficacy of 
psilocybin-assisted treatment for substance use disorders.22,23 The first study, led by 
Matthew Johnson at Johns Hopkins University, was an open-label, dose-escalating study 
to determine the safety and feasibility of oral psilocybin as an adjunct to tobacco smoking 
cessation treatment in 15 tobacco-dependent adults23. Oral psilocybin was administered 
in a moderate (20 mg/70 kg) and then high (30 mg/70 kg) dose during two treatment 
sessions at five and seven weeks, with an optional third session at week 13. Prior to the 
first psilocybin administration, subjects attended four sessions of manualized intervention 
consisting of CBT for smoking cessation and preparation for the drug sessions. Results 
demonstrated substantial decreases in nicotine use among subjects. At the six-month 
follow up, 80% of subjects (12/15) showed seven-day point prevalence abstinence (p = 
0.001), and 73% (11/15) were biologically confirmed to have quit smoking. This 
abstinence rate greatly exceeds rates commonly reported for other behavioral and/or 
pharmacological smoking cessation therapies, which are typically less than 35%.23 
Importantly, no significant treatment-related adverse effects were found.  
The second study, led by Michael Bogenschutz, investigated the efficacy of 
psilocybin-assisted psychotherapy with MET in 10 alcohol dependent individuals.24 
Participants received orally administered psilocybin (0.3 mg/kg and 0.4 mg/kg) in one or 
two supervised sessions at four and eight weeks, with an optional dose increase at week 
eight along with nine total MET sessions. This study found a significant increase in 
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abstinence among subjects following psilocybin administration (p < 0.05) with gains 
largely maintained at follow-up to 36 weeks. Furthermore, the intensity of effects in the 
first psilocybin session was found to be a strong predictor of change in drinking during 
weeks five to eight (r = 0.76 to r = 0.89). No significant treatment-related adverse effects 
were found.  
2.3.2 Clinical studies of Psilocybin in Other Psychiatric Diseases 
Preceding the research on psilocybin as a potential treatment for addiction, 
psilocybin was investigated during the 1950s to 1970s by researchers seeking to 
characterize its pharmacological and safety profile, as well as its potential therapeutic 
properties. Research demonstrated that psilocybin, similar to LSD, reliably induces 
profound changes in sensory perception, emotion, thought, and sense of self, 
characterized by marked alterations in all mental functions.25 As a result, some therapists 
incorporated psilocybin into their psychotherapy sessions in order to facilitate access to 
subconscious conflicts and memories and found that it led to the successful treatment of 
many previously therapy-resistant patients.26  
In the modern era of psychedelic research, more rigorous studies have been 
conducted to investigate the psilocybin’s therapeutic potential in a variety of mental 
health disorders. For example, in 2006, a dose-escalating proof-of-concept study was 
conducted to test the effects of varying doses of psilocybin on symptoms of obsessive-
compulsive disorder (OCD)27. The study included nine adults with symptomatic OCD 
who received doses of psilocybin ranging from very low (25 g/kg) to very high (300 
g/kg). Dosing escalation occurred sequentially, at least one week apart.  Results found 
that all doses produced significant decreases in OCD symptomatology (measured via the 
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Yale-Brown Obsessive-Compulsive Scale, YBOCS) during one or more of the testing 
sessions. Investigators concluded that psilocybin was associated with acute reductions in 
core OCD symptoms in this population.27,28 
Another dose-escalating study investigated safety and efficacy outcomes for up to 
six months in 20 adults with moderate to severe treatment resistant depression.29 Oral 
psilocybin was administered at a low dose (1 x 10 mg) followed by a high dose (1 x 25 
mg) one week later. Results revealed a significant decrease in self-reported depression 
scores in all participants relative to baseline, which lasted up to the last follow-up at six 
months (Cohen’s d = 2.2 at week 1 and 2.3 at week 5; both p < 0.001). Additionally, four 
participants met the criteria for remission at the five-week time point through the last 
follow-up at six months (Cohen’s d = 1.4, p < 0.001).28,29  
Other psilocybin research has focused on evaluating its efficacy in treating 
anxiety and depressive symptoms related to advanced-stage cancer diagnoses.30-32 In a 
2011 randomized, double-blind, placebo-controlled crossover study, 12 adults with 
advanced-stage cancer and reactive anxiety were treated with either 0.2 mg/kg of oral 
psilocybin or oral placebo (niacin, 250 mg) in a randomized order.30 Anxiety and 
depression outcomes revealed an overall decrease in scores compared to niacin placebo 
by almost 30% from the first treatment session to one month after the second session (t11 
=  -2.17, p = 0.05); this difference was sustained and became significant at the six-month 
follow-up point (t7 = 2.71, p = 0.03). Authors observed that psilocybin produced mood-
elevating effects that persisted after the acute effects of the drugs, facilitated therapeutic 
bonds, and ameliorated underlying psychological demoralization.  
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A notable limitation of this study is that a relatively low dose of psilocybin (0.2 
mg/kg) was chosen for the experimental condition. This could have accounted for the 
modest effects found for psilocybin on anxiety and depression outcomes. Similar studies 
conducted in the 1960s and 1970s, which utilized much higher doses of hallucinogens, 
reported that subjects experienced profound psychospiritual epiphanies, which correlated 
with therapeutic outcome. These results are consistent with other recent studies that have 
demonstrated an association between higher doses of hallucinogens and transcendent 
states of consciousness.31,33,34  
Two subsequent RCTs that investigated the effects of psilocybin in this 
population. The first investigated the effects of psilocybin doses (high vs. low) on 
anxiety- or depressive-related outcomes in 56 adults with cancer.31 This study used a 
double-blind crossover design to randomize subjects (N = 56) to one of two sequences 
involving a low dose (“placebo-like”) or high dose of oral psilocybin. Primary outcome 
measures of depression and anxiety demonstrated sustained and statistically significant 
improvements following high-dose psilocybin treatment vs. placebo for up to six months.  
The second study, which investigated the efficacy of a single dose of psilocybin 
vs. placebo in conjunction with psychotherapy in 29 individuals, found similar results.32 
In this crossover study, 29 subjects were given a single dose of 0.3 mg/kg psilocybin or 
250 mg niacin, both in conjunction with psychotherapy, with crossover occurring at 
seven weeks.  Results found that the group that received psilocybin first showed 
“immediate, substantial, and sustained” clinical improvements in anxiety and depression 
scores, which lasted through the seven-week time period between treatments and up to 
the six-month follow-up. The group that received niacin first showed transient reductions 
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that were not sustained at seven weeks. After these subjects received psilocybin, 
immediate and sustained reductions in anxiety and depression were observed 35. In all, 
approximately 60-80% of the 29 total patients, experienced enduring and clinically 
significant reductions in depression or anxiety at the six-month follow-up32.  
Taken together, these studies demonstrate the safety and feasibility of psilocybin-
assisted treatment when administered in a controlled clinical setting to individuals with 
varying mental health disorders. Furthermore, they lend substantial support for the 
efficacy of psilocybin in these populations.   
2.3.3 Safety Considerations for Psilocybin Administration 
Additional clinical studies on psilocybin in healthy volunteers further support the 
feasibility and safety of psilocybin-assisted psychotherapy.19,24,27,31,32,34,36,37  Studies on 
the psychopharmacological properties of psilocybin have found that when psilocybin is 
ingested by humans it is rapidly enzymatically cleaved to produce psilocin, which exerts 
its primary psychoactive effects at serotonin 5-HT2A/C receptor sites in the brain. The 
bioavailability of oral psilocybin is approximately 50%, and the half-life of psilocin in 
blood is two to three hours. Psychoactive effects become noticeable within one hour of 
administration, peak around two hours, and disappear around six hours.28,38 Accordingly, 
protocols for clinical trials have mandated that subjects be observed until about eight 
hours after psilocybin dosing.  
A meta-analysis of eight double-blind placebo-controlled studies of 110 healthy 
volunteers who had received oral psilocybin ranging from 45-315 g/kg in one to four 
sessions, demonstrated that the psychomimetic and physiologic effects of psilocybin are 
dose-dependent.28,36,39,40 Common symptoms included profound changes in mood, 
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perception, thought, and self-experience. Importantly, most subjects described the 
experience as pleasurable, enriching, and non-threatening. Factors other than dose have 
also been reported to modulate psilocybin’s overall effects, such as personality structure 
and setting (i.e. environment). See Section 2.4.1 for more on the effects of set and setting. 
The most commonly reported adverse psychological events of psilocybin were 
anxiety, negative emotional states, and paranoid/delusional thinking, and the most 
commonly reported physical effects were increased blood pressure, heart rate, and mild 
nausea and headache.28 In order to maximize safety in clinical trials with psilocybin, a 
structured and supportive intervention protocol has been established for researchers to 
follow.28,41 
Based on the available literature, researchers have not found evidence of addictive 
properties of psilocybin. Previous clinical studies with individuals with no or minimal 
(less than 10 lifetimes uses and no use within the last five years) history of hallucinogen 
use, who were given psilocybin in the context of a supervised and controlled research 
setting, concluded that, on follow-up, there were no incidents of illicit hallucinogens 
abuse in these subjects. Additionally, a retrospective analysis of the acute, short- and 
long-term subjective effects of psilocybin in healthy humans collected from previously 
conducted double-blind, placebo-controlled trials, revealed that the majority of 
participants reported “no change” in their psilocybin use following study drug sessions, 
as well as “no change” in their overall drug consumption habits (i.e. use of alcohol, 
nicotine, cannabis, MDMA). Those who did report changes often described decreased 
consumption after psilocybin28,39.  Based on this evidence, it is not expected that the 
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hallucinogen-naïve participants in this study will develop dependence after psilocybin 
exposure.  
2.3.4 Safety Considerations for Ketamine Administration 
Ketamine is a dissociative anesthetic that is widely and safely used intravenously 
(IV) and orally in a clinical setting as a short-term anesthetic in doses ranging from 1-2 
mg/kg administered IV, or 4-11 mg/kg administered intramuscularly. (Note: dissociative 
anesthesia is a form of anesthesia that lacks complete unconsciousness but is 
characterized by catatonia, catalepsy, and amnesia).42  Ketamine is classified as an 
“atypical hallucinogen” due to its psychoactive properties. At certain doses it produces 
dissociative and psychomimetic effects similar to those of classic hallucinogens, 
including enhanced sensory perception, emotional connectedness, feeling of unreality, 
visual hallucinations, and altered perceptions of self and time.43 Unlike classic 
hallucinogens, which are primarily mediated by agonist action at 5-HT2A receptors, 
ketamine is a moderate affinity non-competitive N-methyl-D-aspartate (NMDA) receptor 
antagonist.44   
Ketamine’s psychopharmacological effects are dose- and concentration-
dependent.45 Lower doses (i.e. 0.1 mg/kg administered IV over 40 minutes) induce a mild 
state of euphoria that is similar to that produced by a glass of wine, whereas higher 
subanesthetic doses (i.e. 0.5 mg/kg, IV over 40 minutes) produce alterations in sensory 
perception, feelings of unreality, and in some subjects mild psychosis.42,43,45 Ketamine 
has been found to unfavorably affect cognition (i.e. decrease mental sharpness, recall, and 
recognition, as well as explicit and implicit memory) either during or shortly following 
administration.43 During ketamine infusion, it is common for the perceptual effects to be 
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accompanied by anxiety. At doses where it alters perception, it also produces nystagmus 
and this symptom is associated with nausea and, in some cases, vomiting. In patients who 
are sensitive to ketamine-induced nausea, this symptom may be managed by pretreatment 
with odansetron, which does not seem to alter its therapeutic or psychological effects 
(Robert Ostroff, personal communication). In healthy subjects, ketamine typically 
produces a mild elevation in blood pressure and pulse rate that typically does not require 
medical intervention. Repeated ketamine administration appears to be safe when 
managed clinically. However, long-term heavy recreational use of ketamine, which can 
reach daily levels of 100-times the therapeutic dose, may lead to flashbacks, attentional, 
and other cognitive dysfunctions.42,43,46-48 
Ketamine has proven to be a desirable drug due to its short half-life and lack of 
clinically significant severe adverse effects. In addition to its anesthetic action, it also 
possesses analgesic effects, anti-inflammatory effects, and antidepressant activity. 
Repeated subanesthetic ketamine has been shown to improve clinical outcomes for 
treatment resistant depression.49-51 
2.4 Review of Relevant Methodology 
2.4.1 Study Design and Possible Confounders 
The unique challenges of conducting experimental research with psychedelics has 
been discussed extensively throughout the literature.19,52-56 These challenges stem from 
the unique properties of psychedelic drugs and include design issues relating to subject 
selection, the difficulty of blinding to the subjective effects of the drug, and the 
possibility of complex interactions between psychological and environmental factors 
prior to, during, and after drug administration. 
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Prior hallucinogen experience 
With regards to the selection of experimental subjects, an important consideration 
is a subject’s prior hallucinogen experience. Previous studies have used varying selection 
criteria for hallucinogen experience. For example, the open-label study with psilocybin 
for AUD treatment required that individuals have no hallucinogen use in the previous 30 
days, and lifetime use not exceeding 10 occasions.24 In contrast, the open-label trial on 
nicotine dependence required all subjects to have had at least one prior and well-tolerated 
occasion of hallucinogen exposure.23  
In this proposed study, we believe it will be important to enroll only hallucinogen-
naïve participants so that they will not be able to recognize or differentiate between the 
psychedelic drug effects of psilocybin and ketamine due to a lack of previous experience. 
This will help to maintain the blind. This is particularly important in a trial with 
psychedelics because these drugs have been shown to be particularly susceptible to 
expectancy bias – that is,  the individual’s state of mind and expectations when taking the 
drug strongly influence the nature of the drug experience. Thus, minimizing expectancy 
bias enables us to better control the quality of the psychedelic experience.  This selection 
criteria will also enable use to avoid selection bias, where individuals who have 
previously had positive experiences with hallucinogens may be more likely to participate.  
Maintaining the double-blind 
Maintaining the double-blind in studies with psychedelics is considerably difficult 
due to the pronounced acute subjective and objective effects of these drugs, which 
provide subjects and investigators with ample clues for identifying the experimental 
condition. To a certain degree, this problem is shared by other psychoactive drugs (i.e. 
stimulants, sedatives, and opioids) that produce discriminable effects, and typically, the 
 21 
solution is to use an active placebo in lieu of an inert placebo. However, in trials with 
psychedelics, even active placebo has been easily distinguished from the experimental 
condition by participants and investigators.29  
Previous psilocybin trials have used active controls such as niacin, ephedrine, and 
methylphenidate, due to their ability to induce some of the same mild physiological 
symptoms as psilocybin (i.e. sense of warmth, arousal, tingling sensation, and flushing, 
nervousness, and/or increased positive mood) without altering the subject’s psychological 
state.30,32 However, as Grob and his team discovered in their trial assessing the efficacy of 
psilocybin vs. niacin placebo in advanced stage cancer patients, “the drug order was 
almost always apparent to subjects and investigators whether the treatment was 
psilocybin or placebo.” Similarly, Ross and his team concluded that staff guessed 
correctly 97% of the time whether the participant was administered psilocybin or niacin 
placebo rendering blinding completely unsuccessful. In fact, it is estimated that in RCTs 
with LSD or psilocybin, session monitors (therapists present during the drug sessions) 
were able to accurately discriminate between these experimental drugs and active 
placebos in 77-95% of the time.55  
In other trials, very low (“placebo-like”) doses of psilocybin have been used with 
the intention of providing noticeable psychoactive effects without the therapeutic effect 
of higher doses. In the psilocybin trial for OCD, a very low dose (25 g/kg) psilocybin 
placebo was concluded to be an ineffective blind: “subjects experienced stronger than 
anticipated response to this dose, and its clinical effects were also greater than 
anticipated. This response to VLD impedes the use of VLD as a  placebo comparator.”27 
Another trial that used a very low dose of psilocybin as a placebo, had somewhat more 
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success in maintaining blinding, stating that “blinding procedures provided some 
protection against a priori monitor expectancy strongly determining outcomes of the 
psilocybin dose manipulation.”  
A limitation to a low-dose psilocybin placebo is that it is difficult to exclude the 
possibility that even a low-dose psilocybin placebo control may have some 
psychomimetic properties and partially contribute to treatment effects (as mentioned 
earlier). “A wiser choice,” one investigator advises, “may be a control that has a different 
mechanism of action yet is still capable of producing similar psychoactive symptoms so 
that participants may remain blinded to their condition/treatment.”30 Heeding this advice, 
we have selected ketamine as the control condition in our study, since it closely mimics 
psilocybin’s psychoactive effects, while still possessing a radically different mechanism 
of action from psilocybin.57  
This design will be in contrast to Bogenschutz’ current study on psilocybin for 
AUD, which is using diphenhydramine (50 mg) as an active control. (Diphenhydramine 
at this dose has a side effect profile that includes pupil dilation, facial flushing, 
hallucinations, and ataxic gait, which overlap with some of the physiologic side effects of 
psilocybin). We believe that blinding will be significantly compromised in this RCT.  
Set and Setting 
An individual’s state of mind and expectations when taking a psychedelic, as well 
as the context (i.e. physical and interpersonal environment) in which the individual takes 
the drug significantly contribute to the overall quality of the drug experience. 
Consequently, the effects of hallucinogens can vary markedly from individual to 
individual and from session to session. This idea was introduced early on in psychedelic 
research, and dubbed “set and setting.”55,58,59  The elements of “set and setting” are 
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essential to account for within the design of a clinical trial on psychedelics because the 
overall quality of the drug experience is believed to mediate the persisting therapeutic 
effects of the drug.  
Research to support this idea includes the finding that “pre-session negative mood 
consisting of anxiety or depression has been shown to significantly predict anxious or 
other negative experiences during the session.”41 In addition, work by Griffiths and his 
team with psilocybin in healthy individuals found that the presence/absence, and quality 
of the mystical experience during the drug’s acute effects were significant predictors of 
beneficial change in volunteers. While research to systematically evaluate how specific 
elements such as set and setting may impact therapeutic outcomes is lacking, this idea is 
still generally accepted by psychedelic researchers.  
Accordingly, Johnson and colleagues have published a set of guidelines for 
researchers to follow in order to control for the variables discussed here, maximize 
therapeutic potential, and ensure patient safety. These guidelines are based on previous 
research and are closely followed by researchers in this field. In addition to these 
guidelines, clinically validated instruments have been developed to qualify the 
dimensions of the drug experience and its overall intensity. All of the methods relevant to 
this proposal will be incorporated into our design (see Section 3.6.2).  
Crossover Design 
Taking into consideration the various challenges of RCTs with psychedelics, as 
well as our study’s objectives, we selected a crossover design. Crossover designs have 
been used extensively in early-phase trials, including in studies with psilocybin in normal 
volunteers and individuals with anxiety and depressive disorders19,30-32. The most 
common type of crossover design consists of a two-period, two-treatment design wherein 
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subjects are randomly assigned to receive either treatment A and then B, or B and then A. 
A crossover design is ideal for studying treatment of chronic conditions in which clinical 
status is unlikely to change without treatment.  It is also best for studying treatments that 
have rapidly evident effects.60,61 A strength of this design is that it reduces between-
patient variation, since subjects act as their own controls. Additionally, since all subjects 
receive the experimental treatment, the issue of excluding some individuals from a 
potentially beneficial treatment does not exist.  
A limitation of the crossover design is the potential for carryover effects. 
Carryover occurs when the effect(s) of the treatment administered in the first period 
carryover into the second treatment period. In order to prevent carryover effects, we will 
include a four-week active washout period between treatments A and B (during which 
only MET will be administered). Based on previous research on the time course of acute 
effects of ketamine and psilocybin, we believe this length of washout is sufficient.30-
32,43,49,62 Another limitation is the possibility of a period effect,  which occurs when the 
order in which the two treatments are administered affects the outcome. We will account 
for these limitations in our statistical analysis by running a between-group analysis to test 
the effect of the active intervention, and a within group analysis to test the effect of order. 
2.4.2 Primary and Secondary Outcomes 
There are no generally accepted criteria for success in addiction treatment 
research.19 In AUD research, there is a consensus to include alcohol consumption as a 
measure of treatment outcome, however, researchers debate over how to operationalize 
alcohol consumption. The FDA accepts complete abstinence and no HDD as clinical trial 
endpoints.5 Dimensional measures that include abstinence are, time to first drink, time to 
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relapse, and longest duration of abstinence. Although long-term total abstinence is the 
most desirable outcome, recent evidence suggests that these endpoints may be overly 
strict and may not capture all individuals who respond to a medication. As the authors of 
Project MATCH point out, alcohol abusers demonstrate improved outcomes over time, 
therefore, a dichotomous measurement of abstinence or drinking is not sensitive to 
improvement.63,64  
Other dimensional measures that have been proposed include percent days 
abstinent, percent heavy drinking days, and drinks per drinking day. The Alcohol Clinical 
Trials Initiative (ACTIVE) workgroup and affiliated researchers have advocated for such 
alternate endpoints, arguing that individuals who are able to reduce their alcohol 
consumption to low-risk levels during treatment do not substantially differ from 
abstainers in terms of healthcare utilization or medical costs and they are able to sustain 
this reduction in alcohol consumption over several years.5  
In 2001, an NIAAA panel designated PHDD as the optimal outcome measure for 
future alcohol treatment efficacy trials because it can capture both abstinence and 
improvement over time.63 Accordingly, many recent large-scale trials have used these 
alternative endpoints.11,13,63-70 In keeping with the NIAAA recommendations and the 
trends of recent trials (including Bogenschutz’s studies on psilocybin for AUD), this 
outcome measure is the most logical choice for this study; it will enhance validity by 
allowing for consistency in evaluation and cross-study comparisons.  
In order to capture this data, the timeline follow-back (TFLB) instrument will be 
used. The TFLB is a daily drinking estimation method that been validated by the 
American Psychiatric Association and the NIAAA.71 The NIAAA recommends it as the 
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measure of choice when drinking is variable or when relatively precise estimates of 
drinking are needed (i.e. frequency of drinking at specific levels). An alternative means 
of assessing DDE is through Form 90, however, TFLB has been determined the most 
psychometrically sound and widely used DDE method.63 An important advantage of this 
method is that researchers are able to reanalyze the raw data to generate alternative 
drinking outcomes of interest not assessed in a study (i.e. percent days abstinent, days to 
first drinking day, number of days to first drink), which enhances reliability. Limitations 
of this method include that it requires more resources such as interviewer and participant 
time, training, and increased burden on the respondents, which could increase attrition 
rates.  
The non-drinking outcome measures in this study will be three well-established 
mediators of addictive behavior – self-efficacy, craving and motivation – that have been 
implicated as significant predictors of treatment outcome in alcohol addiction and that are 
potentially modifiable through therapeutic use of classic hallucinogens.72 Self-efficacy is, 
“the conviction that one can successfully execute behavior required to produce the 
[desired] outcomes.”72 It provides a means to predict and understand psychological 
changes that occur during treatment. Motivation can affect drinking by “[influencing] 
patients to seek, complete, and comply with treatment and make successful long term 
changes in drinking.”72 Hallucinogen treatment is theorized to enhance motivation 
through several mechanisms. During acute intoxication, hallucinogens are known to 
cause a subjective experience of mysticism and/or other novel psychological experiences 
or insights. This in turn may increase one’s belief in the possibility of change (self-
efficacy), heighten one’s awareness of negative consequences, and change one’s 
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perspective in favor of a greater desire to change, which together may enhance one’s 
motivation.72 MET may further facilitate this process by directly targeting motivation as 
the main mechanism of behavioral change.  
Craving is a multi-dimensional construct which includes motivational, affective 
and cognitive components.72 Many studies have demonstrated a positive relationship 
between craving intensity and relapse. While there are yet to be any clinical trials with 
hallucinogens to investigate the role of alcohol or drug craving in treatment, Bogenschutz 
recommends that future trials include assessment of craving to investigate this question. 
He hypothesizes that, “stimulation and persistent activation of serotonergic pathways 
could affect craving by diminishing attentional bias, normalizing stress response, 
improving mood, or diminishing anxiety.72 
Additional measures will be included to capture the quality of the participants’ 
acute hallucinogenic experience. This is an essential element of hallucinogenic trials 
since a basic principle of the psychedelic treatment model holds that the quality of the 
acute experience mediates long-term improvements in mental health.33 Indeed, 
Bogenschutz and his team found this to be true in their pilot study on psilocybin for 
alcoholism which demonstrated that both mystical experience and broader measures of 
the intensity of subjective effects were associated with improvement in drinking.24 “The 
patient’s conscious experience during the drug’s acute effects is essential for long-term 
clinical benefit,” Bogenschutz explains.73 The assessments used in this study to capture 
subjective experience of psilocybin will include the APZ Questionnaire (a version of the 
Altered States of Consciousness Rating Scale, ASCRS), to be completed by the 
participants, and a Monitor Session Rating Form (MSRF), to be completed by monitors 
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present during the drug sessions. (The MSRF will expand upon the subjective reports of 
the participants with monitor ratings of participants behavior and affect). The APZ is a 
clinically validated measure, commonly used throughout psychedelic research. In 
addition to capturing subjective data such as mood, perceptions, and cognitions, the APZ 
Questionnaire will also enable a characterization of the intensity of the experience, and 
inform researchers of possible safety considerations. By incorporating this well-
established and commonly used measure into our study, the validity will be enhanced by 
enabling comparisons between other trials. 
An assessment of the presence or absence of the mystical experience as well as its 
quality, is an important component of this study. The mystical experience will be 
assessed by the Mystical Experience Questionnaire (MEQ-30). Numerous clinical trials 
with psilocybin and other classic hallucinogens have attempted to evaluate the occurrence 
and character of individual mystical experiences that hallucinogens have been found to 
induce due to cumulative evidence over the years that it may serve as a valuable predictor 
of positive outcomes.33,34,72,74-76  
Dating back to 1950s, Drs. Hoffer and Osmond noticed an unexpected effect of 
LSD in alcoholic patients: it seemed to induce an experience “so profound and 
impressive that [one’s] life experience in the months and years to follow [would become] 
a continuing growth process.” As other researchers at the time similarly noted, LSD 
evoked a “transcendent, overwhelming, conversion-like experience” in patients and,  
“clients who [made] successful recoveries often [attributed] their success to a spiritual 
experience or enlightenment.” Bill Wilson (the founder of Alcoholics Anonymous) 
credits the spiritual experiences he had while using LSD as the impetus for his sobriety.  
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In his treatment model for Alcoholics Anonymous, he incorporates a similar concept, 
which emphasizes the importance of an experience of spiritual insight in the path to 
sobriety. 73 77 Other Twelve-Step programs are similarly based on the idea that spiritual 
change can bring about recovery from addiction.72  
Contemporary addiction research has examined the role of a spiritual experience 
in recovery. One large study on alcoholism treatment found that subjects who reported a 
recent spiritual awakening were found to have markedly increased rates of 12-month 
continuous abstinence compared to those who did not report this experience (odds ratio = 
3.9).78 In another study, 82% of individuals who reported a spiritual awakening between 
baseline and follow-up reported abstinence compared to 55% of those not reporting such 
an experience (55%) (X2 = 26.48, p < 0.001).72,79 Recent studies with psilocybin have 
demonstrated that the self-reported “mystical” dimension experienced while taking 
psilocybin significantly predicts the lasting personal significance of the experience.34,37   
More research is needed to further investigate the role of the mystical experience in 
alcohol treatment.  
2.4.3 Inclusion and Exclusion Criteria 
The inclusion and exclusion criteria for this study are based on established 
guidelines for the safe administration of hallucinogens in human volunteers, as well as 
Bogenschutz and his team’s pilot and RCT studies on psilocybin for AUD, and an 
ongoing study by McAndrew and her team on ketamine-assisted-therapy for 
AUD).24,41,80,81 In accordance with the guidelines, all participants will be in good general 
health, as assessed by detailed medical history, physical examination, 12-lead ECG, 
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blood chemistry profile, hematology, and urinalysis. Pregnant women or those not 
practicing effective means of birth control will be excluded.  
Due to the side effect of psilocybin and ketamine to moderately increase pulse 
and both systolic and diastolic blood pressure, volunteers will be excluded if they have 
uncontrolled hypertension (defined as a blood pressure exceeding 165 systolic and 95 
diastolic (mmHg), averaged across four assessments on at least two separate days) or 
serious ECG abnormalities (i.e. evidence of ischemia or myocardial infarction)28,41.  
Participants taking the following medications on a chronic basis (greater than 30 days) 
will be excluded from the study due the potential of these medications to interact with 
psilocybin: tricyclic antidepressants, lithium, serotonin reuptake inhibitors, monoamine 
oxidase inhibitors, haloperidol.  
Thorough psychiatric interviews using the Structured Clinical Interview-5, 
Alcohol Revised (SCID-5-AR) assessment will be conducted to identify and exclude 
individuals with contraindicated psychological disorders (see Appendix C). This 
psychiatric screening criteria is important for minimizing the chance (admittedly, already 
low) of precipitating a longer-term psychotic, or adverse emotional or behavioral reaction 
by hallucinogen administration.28,41 It will also enable us to decrease the chance that 
symptoms from such disorders are inadvertently misattributed to the action of psilocybin 
or ketamine. Individuals with other medical conditions that will preclude safe 
participation in this study will be also be excluded (see Appendix C). 
In order to minimize the potential for confounding, participants with a history of 
cocaine, psychostimulant, opioid or cannabis dependence within the previous 12 months 
will be excluded, as well as those participating in any formal treatment for alcohol 
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dependence (12-step meetings are not considered treatment). Participants must have a 
desire to stop or decrease their drinking, and at least two heavy drinking days (HDD) 
within the previous 30 days. 
2.4.4 Intervention 
Pharmacological intervention: 
The two leading candidates for application in the treatment of addiction are LSD 
and psilocybin, as supported by the evidence presented here19. While LSD has the 
advantage of an extensive body of literature on alcoholism treatment trials from the 
1950s-1970s, psilocybin, has other advantages. Among them, psilocybin has a shorter 
duration of action (four to six hours) compared to LSD (eight to twelve hours), making it 
more amenable than LSD to administer outpatient. Additionally, it has been found to be 
more strongly visual, less emotionally intense, more euphoric, and with fewer panic 
reactions and less chance of paranoia than LSD30. These properties, together with the 
evidence favoring psilocybin for the treatment of a variety of mental health disorders 
have led us to choose psilocybin as the intervention in this proposed study.  
Psilocybin dose: 
In keeping with the psychedelic treatment model (vs. the psycholytic treatment 
model; see “Psychosocial Intervention” section below for further information), we will 
use a single high dose of psilocybin (0.3 mg/kg) in conjunction with several treatment 
sessions. In completed clinical trials studying oral psilocybin, doses have ranged from 
0.045 mg/kg (very low dose) to 0.428 mg/kg (very high dose), all of which were reported 
to be safe and without serious adverse events. In Bogenschutz’s open-label trial on 
psilocybin for AUD, participants received 0.3 mg/kg during the first session, and 0.4 
mg/kg during the second session. In his follow-up RCT, doses will range from 25 mg/70 
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kg to 40 mg/70 kg. In the study on tobacco dependence, oral psilocybin was administered 
at a low dose (20 mg/70 kg) and a high dose (30 mg/70 kg) with an option for a third 
dose (low or high). Based on these trials, we will administer 30 mg/70 kg of psilocybin in 
a single session. Additional support for using this high dose comes from the literature, 
which consistently demonstrates that higher doses of psilocybin lead to better 
outcomes.19,28,34,37  Since all participants in this study will only be getting one dose of 
psilocybin, it makes sense to maximize the possibility for therapeutic efficacy. While a 
higher dose does increase the risk of adverse events, these events are typically non-
serious and transient, resolving by the end of the dosing day. Furthermore, common 
adverse events such as fear and anxiety respond well to reassurance and have not required 
pharmacological intervention in previous studies.28  
Ketamine dose: 
Ketamine will be administered at a subanesthetic dose of 0.5 mg/kg during a 40-
minute IV infusion in order to blind participants, care providers, and outcome assessors 
to the experimental treatment. This will be the first clinical trial with psilocybin to use 
ketamine as an active placebo. This dose was chosen due to evidence from previous 
experimental trials that it reliably exerted broad influences on consciousness and 
perception.42,43 These effects typically emerge within 10 minutes of the start of the 
infusion, and subside within 40 minutes of treatment termination, similar to the time 
course of psilocybin’s effects. (Note, little to no psychoactive effects were observed at 
the dose of 0.1 mg/kg).  
While ketamine has been administered orally in certain clinical contexts, there is 
far less research on the safety and pharmacodynamic effects of orally administered 
ketamine compared to IV-administered ketamine82. Thus, we will have to employ a 
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double dummy design in order to disguise the ketamine treatment from the experimental 
session with psilocybin. 
While the potential for ketamine to confound results cannot be excluded, 
particularly given previous pilot work conducted in Russia in the 1990s that administered 
ketamine in conjunction with psychotherapy for the treatment of AUD, we do not 
anticipate this.83 This previous work had serious methodological flaws preventing any 
significance conclusions on potential efficacy to be drawn.  Furthermore, a more recent 
double-blind treatment trial investigating the therapeutic potential of NMDA receptor 
antagonists for AUD found that memantine did not have any significant effects on 
reducing drinking behavior in alcohol-dependent patients.84  
Psychosocial intervention: 
There are two treatment models which have consistently been used throughout 
clinical trials of psychedelic-assisted psychotherapy, and which have their origins in early 
research with LSD therapy for alcoholism in the 1950s57. The two models, termed 
psychedelic and psycholytic therapy, are based on different theoretical frameworks. 
Psychedelic therapy involves high doses of a psychedelic (typically LSD, 200-800 g) 
administered once or on a few occasions, with the goal of inducing a “peak-psychedelic,” 
or mystical, experience.19,57. In contrast, in the psycholytic model, low to moderate doses 
of hallucinogens (i.e. LSD 50-100 g or psilocybin 10-15 mg) are administered on 
multiple occasions over months to years. The psycholytic treatment model incorporates 
psychedelics  into traditional psychoanalytic therapy, in order to accelerate the 
therapeutic process.26 The psychedelic model has been used across various populations 
including severe alcoholics, narcotic addicts, and individuals with existential anxiety 
related to cancer-diagnoses and depression, with reported success.57,85-87 Most of the 
 34 
studies within the addiction treatment field (both early and recent) have used the 
psychedelic model, including the two open-label trials on psilocybin-assisted 
psychotherapy for AUD and tobacco dependence. Thus, the psychedelic treatment model 
will be used in this study.   
In keeping with the behavioral intervention used in Bogenschutz’s trials on 
psilocybin for AUD, the psychosocial intervention utilized in this study will be MET. 
While alternative approaches could be used, such as CBT or TSF, the key elements 
believed to be driving change through hallucinogenic-assisted therapy are also central 
targets of MET (i.e. motivation), thus when paired, they can work synergistically to affect 
change. MET will be delivered using a structured approach that incorporates the 
principles of motivational interviewing established in the Motivational Enhancement 
Therapy Manual.88 
2.5 Sample Size 
The within group effect size was approximated from Bogenschutz’s pilot study on 
psilocybin for AUD. In this study it was found that PHDD decreased during the four-
week period following psilocybin administration relative to the baseline by a mean 
difference (SD) of 26.0 (22.4), 95% CI 8.7-43.2, p = 0.008. Based on this data, we 
estimated a slightly more conservative difference of effect between psilocybin and 
ketamine of d = 1.0. Due to an absence of data on the level of outcome in the ketamine 
group, we estimated the effect of ketamine to be half the magnitude of the effect of 
psilocybin (d = 0.5). This calculation yielded a sample size of 57. 
2.6 Conclusion 
 New treatments are needed for AUD, and this new era of psychedelic research has 
produced significant evidence for the promise of psilocybin-assisted therapy as a novel 
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treatment option for AUD. This proposed study will aim to help fill the gaps in current 
research. It is our hope that our results will provide further evidence for the therapeutic 
role of psilocybin in addiction and that our study design may serve as a model for future 
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Chapter 3 – Study Methods 
3.1 Study Design 
This study will be a 10-week randomized, double-blind, active-placebo-controlled 
crossover trial to evaluate the effect of psilocybin-assisted treatment on drinking 
outcomes relative to a ketamine control.  A double-dummy design will be employed in 
order to disguise psilocybin from ketamine (see Figure 1). Participants will be randomly 
assigned to two separate dosing sequences: (1) psilocybin and ketamine placebo, 
followed by ketamine and psilocybin placebo or, (2) ketamine and psilocybin placebo, 
followed by psilocybin and ketamine placebo. The drug administration sessions will 
occur within the context of 12 psychosocial sessions.  
 
Figure 1: Intervention Design  
 
3.2 Study Population and Sampling  
The study population will include English-speaking adults, aged 25-65 with a 
diagnosis of alcohol use disorder (in accordance with DSM-V criteria).  Resources from 
the Yale Center for the Translational Neuroscience of Alcoholism (CTNA), the VA 
Alcohol Research Center (ARC), the Connecticut Mental Health Center (CMHC), and 
the Alcoholism Treatment Center at Yale will be utilized for support in enrolling 
subjects; clinicians at these sites will be informed of this study and asked to refer eligible 
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and interested patients. Convenience sampling will be used to include heavy drinkers 
who are motivated to seek help.  
Participants will also be recruited from the general population using advertising 
and recruitment media (i.e. Craigslist, Google, Twitter, Facebook, cable TV, and print 
advertising and flyers). Advertisements will be designed to target heavy drinkers at 
places and times they are expected likely to consider getting help for their drinking (i.e. 
late-night TV ads, early morning radio and TV ads, and print advertising in heavily 
trafficked urban areas).  
For those individuals interested in participating who have provided verbal 
consent, a pre-screen phone interview will be given to determine initial eligibility. Those 
who pass this screening will be scheduled for an in-person screening visit at the 
Alcoholism Treatment Center at Yale, where a trained research staff member will 
administer the SCID-5-RV to provide a diagnosis of AUD1. Eligible subjects must meet 
the inclusion and exclusion criteria outlined below in order to be invited. Once invited, all 
participants will be randomly assigned to a treatment sequence. 
3.3 Eligibility 
Eligibility will be determined through assessment of the patient by a clinician, or 
other trained study personnel. The subject’s clinical and medical information will be 
reviewed by the research staff for any contraindications to research participation. The 
inclusion and exclusion criteria will be used as a guide for eligibility. See Appendix C for 
full inclusion/exclusion criteria. 
In preparation of drug administration sessions participants must agree to: (1) Ingest 
only alcohol-free liquids after 24:00 (midnight) the evening before the drug 
administration session, and refrain the day of and the day after each drug administration 
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session. (2) Refrain from the use of any psychoactive drug, with the exception of caffeine 
or nicotine, within 24 hours of each drug administration session (3) Not use caffeine or 
nicotine for two hours before and six hours after ingesting the drug, or until therapists 
deem it safe to do so. 
3.4 Subject Protection and Confidentiality  
Prior to recruitment, we will attain Institutional Review Board (IRB) approval 
through the Integrated Research Enterprise Solution-IRB submission system. All 
necessary accompanying documents will be accessed through this system and submitted 
along with the protocol application (see Appendices D-F).  Study goals, timeline, 
procedures, confidentiality practices, and all potential risks, discomforts, and benefits of 
participation will be clearly outlined. Once IRB approval is obtained, a separate 
Investigational New Drug (IND) application will be submitted.   
Protection of participants’ research data will be compliant with Yale University 
Procedure 400 PR.1 and the Health Insurance Portability and Accountability Act 
(HIPAA). All identifiable research data, including recruitment and screening information 
and code keys will be stored on a database located on a secure Yale-ITS network. Access 
to the database will be password protected.  
All subjects considered for participation in this study will be given an informed 
consent and a thorough explanation of the study. All consents will be appropriately 
documented. Risks to participants will be minimized. Selection of participants will be 
equitable, and will not inappropriately exclude based on gender, race, age or other 
criteria. We will not specifically recruit for a category of subjects that require special 
safeguards (i.e. children, non-English speaking, prisoners, pregnant women). Subjects 
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who are females of childbearing potential will require the following additional 
safeguards/considerations upon their enrollment in the study (see Appendix C). 
3.5 Study Variables and Measures  
The intervention will be synthetic psilocybin (0.3 mg/kg) and its control will be 
an inert capsule. Both pills will be delivered by a blinded pharmacist from the Yale 
Investigational Pharmacy and swallowed with 100 ml. of water. The active control will 
be intravenous ketamine 0.5 mg/kg and its control will be intravenous saline 0.9%, both 
of which will be infused over 40 minutes by an anesthesiologist from Yale who will be 
blinded. 
The primary outcome (dependent variable) will be mean percent heavy drinking 
days in each treatment arm, which will be measured with the TLFB method (a calendar-
based form in which people provide retrospective estimates of their daily drinking over a 
designated time period) at baseline, weeks two, six and 10.  Heavy drinking days will be 
defined as days during which participants consume five or more standard drinks (14 g of 
alcohol) if male, or four or more standard drinks if female.  
Several secondary outcomes will be measured. Motivation to change drinking 
behavior (assessed with SOCRATES 8A; see Appendix G), self-efficacy (assessed with 
the AASE; see Appendix H), and craving (assessed with PACS; see Appendix I) will be 
measured at baseline, one day prior to dosing sessions, and one day after dosing sessions. 
The acute subjective drug experience (assessed with the APZ Questionnaire) and the 
mystical experience (assessed with the Mysticism Scale) will be collected seven hours 
following dosing sessions. The APZ is a 72-item yes/no questionnaire and data will be 
expressed as a percentage of maximum possible score. The mystical experience (assessed 
with the MEQ 30) will be measured seven hours following drug administration at weeks 
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two and six. The MEQ 30 will generate a total score, as well as four empirically derived 
factors: mystical; positive mood; transcendence of time and space; and ineffability. The 
monitor ratings (assessed with the MSRF) will be collected during the first six hours 
following drug administration at weeks two and six. The MSRF will involve scoring 
several dimensions of the participant’s mood or behavior, which will be rated on a 5-
point scale from 0 to 4 and expressed as peak scores. Data will be the mean of the two 
monitor ratings at each time point. 
Safety assessments will include: adverse events (collected on an adverse events 
case report form) that will be monitored at every study visit. Cardiovascular measures 
(systolic and diastolic blood pressure, heart rate) will be assessed during medication 
sessions at the following time points: 30, 60, 90, 120, 180, 240, 300 160 minutes post-
dose administration. 
Additional outcomes that will be collected at baseline include demographic and 
clinical characteristics of study participants as follows: sex (male, female), age (mean 
(SD)), race (White, Black, Hispanic, Asian, Other), highest level of education (high 
school or less, some college, college, graduate/professional degree), religious/spiritual 
beliefs (atheist/agnostic, Jewish, Catholic, Christian, other faith/tradition), mean duration 
of alcohol dependence (in years), current tobacco use (yes/no), current marijuana use 
(yes/no), previous alcohol treatment (yes/no; if yes, indicate).  
Alcohol withdrawal will be assessed with CIWA-Ar, (reported as a score from 0-
70, where ≥ 10 is indicative of alcohol withdrawal) at baseline and each drug 
administration session. Urine pregnancy tests (UPT) for women of childbearing potential 
will be collected at baseline and prior to each drug administration session. Breath Alcohol 
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Concentration (BAC) and Urine toxicology screens will be measured at baseline and 
every subsequent visit in order to ensure safety of treatment and validity of assessments. 
See Figure 2 for an outline of data collection timepoints.  
3.6 Methodology Considerations 
At the medical screening visit, subjects will undergo a complete history and 
physical examination and the following tests will be performed: ECG, liver function tests, 
complete blood count, blood chemistries, urinalysis, serum pregnancy test, and body 
mass index. Based on this data, subjects eligible for participation will be enrolled into the 
study. Within two weeks of this screening, the first visit will take place. At this visit 
subjects will meet with the study team including the therapists who will lead the MET 
sessions and drug administration sessions. They will complete all baseline assessments 
and be provided with a calendar of the study visits. Someone from the study team will 
also orient them to the room where the drug administration sessions will take place, and 
participants will be given an opportunity to address and questions or concerns they have. 
After the baseline visit, participants will have four separate visits scheduled over a two-
week period – the first two visits will be MET sessions and the subsequent two will be 
preparation sessions. At week two the first drug administration session will occur. A 
four-week washout period will follow.  During this period there will be a debriefing 
session (the day after the drug session), two MET sessions at weeks three and four, 
respectively, and a preparation session at week six the day prior to the second drug 
administration session. Following the second drug administration session another 
debriefing session will follow the next day, and then MET sessions will occur at weeks 
seven, eight, and nine. (See Appendix J).  
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The following resources will be used to develop and standardize the content for 
the drug administration sessions and psychosocial intervention: (1) Project MATCH 
Motivational Enhancement Therapy Manual (2) Human Hallucinogen Research: 
Guidelines for Safety (3) Supplementary Materials from Bogenschutz’s Pilot Study and 
RCT.2-6 A brief summary of what this will entail will follow. 
3.6.1 Drug Administration Sessions 
No more than one patient will be in a drug administration session on any given 
day. Patients will arrive at the research facility in the morning (8:00-9:00 am) and 
complete all necessary interim assessments. They will be taken to the dosing room where 
they will be invited to relax on a bed in a supine or reclined position with eyeshades 
while music is played through high-quality stereo speakers and earphones. The two 
session monitors will sit on either side of the bed and will be present for the duration of 
the session. Dosing will take place at approximately 10:30 am. Additional measurements 
will be collected as necessary throughout the sessions, as stipulated in Section 3.6. 
Tranquilizing medications (oral lorazepam and risperidone) will be on hand for 
administration if necessary. Monitors will adopt a non-directive, supportive approach, 
allowing the patient to experience a mostly uninterrupted inner “journey”. Upon the 
session’s completion, patients will be picked up from the facility by a close friend or 
relative who will bring them home and stay overnight with them.  
3.6.2 Psychosocial Intervention 
The psychosocial intervention will comprise a total of 12 sessions: seven MET 
sessions, three preparation sessions and two debriefing sessions. The psychosocial 
intervention will be delivered by a team of two therapists (session monitors) who will be 
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present at every session, including the two drug administration sessions. One of the 
therapists will perform the MET sessions, while the other will be responsible for 
preparation before, support during, and debriefing after the drug administration sessions. 
Therapy sessions will be audio-recorded and coded using the Motivational Interviewing 
Treatment Integrity coding system by a rater trained to reliability.7  
The goal of the first preparation sessions will be to conduct a detailed life review, 
including information about the participant’s history, current situation, personality, 
relationships, goals, etc., and to facilitate the development of rapport between the 
participants and the therapists. The second preparatory session will include a review of 
motivation and expectations for the study, detailed information about the physiological 
and psychological effects of the drugs, and advice on how to deal with potential 
dysphoric reactions to the drugs. The participant will be introduced to the aspects of the 
dosing sessions and oriented to the room in which the session will take place. At all 
preparatory sessions, the participant will be given the opportunity to address questions, 
concerns, hopes, and fears related to the drug sessions.  
De-briefing sessions will occur the day after each dosing session to allow the 
participant to reflect on his experience during the dosing session. Open-ended 
questioning techniques will be used to encourage the participant to discuss his experience 
freely. Motivational interviewing techniques will be used to discuss how the session has 
affected the participant’s relationship to alcohol and desire to change drinking behavior.  
3.6.3 Blinding of Intervention 
Double-blind randomization will be maintained by the Yale New Haven Hospital 
(YNHH) Investigational Pharmacy, with joint-assistance from the CTNA. Psilocybin and 
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its placebo will be prepared in identical opaque 0 gelatin capsules. The ketamine and 
saline solutions will be supplied in identical 50-ml syringes containing either 0.9% saline 
or ketamine with the additional volume of saline to total 50 ml. Participants, study 
therapists, investigators, and outcome assessors will be blinded to the drug administration 
conditions. At the end of each dosing session, the session monitors will record their 
guesses as to whether the participants received psilocybin or ketamine. Participants will 
not be asked to record their guesses as to which drug they receive on dosing session days.  
3.6.4 Blinding of Outcome  
Trained research staff will administer the TLFB to collect drinking data on every 
participant. Session monitors will be blinded to the data until the end of the experimental 
period at week 10.  
3.6.5 Assignment of Intervention 
Participants will be equally randomized to the two different dosing sequences via 
a random-numbers chart. Randomization will not stratify for any demographic or clinical 
characteristics. The randomization list will be kept with other study documents in a 
secure location, available only to administrative staff. Upon entry of a new participant to 
the trial, administrative staff will consult the allocation sequence and provide this 
information unblinded to Yale pharmacy staff who will prepare the drugs. The 
pharmacist who delivers the medication and the anesthesiologist to administer the 
infusions will be blinded to the treatments.  
3.6.6 Adherence  
Incentives such as monetary compensation or vouchers will not be used in this 
study. It is our hope that in selecting only individuals with a motivation to change their 
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problematic drinking behaviors that participants will remain in the study until its 
completion. The relatively short length of the study period (10 weeks) will hopefully 
facilitate participant adherence. Nevertheless, some degree of dropout is nearly 
inevitable, so we have accounted for dropout in our sample size calculation. 
3.6.7 Monitoring of Adverse Events:  
In order to monitor for any adverse events (AE) vital signs will be obtained at 
each visit and at multiple timepoints throughout the drug sessions (see Section 3.6). Any 
adverse events that do occur will be collected on an AE case report form at the end of the 
session.  
3.7 Data collection 
Data for the primary outcome, mean PHDD, will be collected with the TLFB 
method by a trained member of the study team at Baseline (data for previous 90 days); 
week 2 (data for previous two weeks); week 6 (data for previous 4 weeks); and week 10 
(data for previous 4 weeks). A trained study staff member will administer all additional 
questionnaires and assessments. The below figure outlines the specific timepoints of data 











Figure 2: Data collection schedule for outcome measures and assessments  
 
3.8 Sample Size Calculation 
We used a t-test calculator to calculate sample size. Assuming a confidence level 
of 1%, an effect size of d = 1.0, and a standard deviation of 22.4 to test a two-sided 
hypothesis for a power of 80% and 10% dropout, we determined that we will need 57 
subjects. We corrected the assumption for the confidence level due to the multiple 
comparisons that would be tested in a crossover design.  
3.9 Analysis 
Descriptive statistics (means and proportions) will be used to describe the 
baseline demographic and clinical characteristics of the study sample. Simple inferential 
statistics will be used to compare the characteristics between the two dose-sequence 
groups at baseline. T-tests will be used to compare continuous variables, and chi-square 
tests will be used to compare categorical variables.  
Between and within-group comparisons will be made for the primary outcome 
and all secondary outcomes (motivation, self-efficacy, craving, mystical experience, and 
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acute subjective effects). For the primary outcome of mean PHDD, the between-group 
analysis will test the effect of the active intervention (i.e. the difference in mean PHDD 
post-psilocybin in Arm 1 vs. the mean PHDD post-ketamine in Arm 2), and the within-
group analysis will test the effect of order. To test for these comparisons we will first test 
the data for skewedness with the Kolmogorov-Smirnov and Shapiro-Wilk tests. If the 
data are not skewed, within-group changes will be analyzed with a paired t-test and 
between-group comparisons will be analyzed with an unpaired t-test. Additionally, mean 
changes in PHDD and all secondary measures at all timepoints will be analyzed using 
repeated measure ANOVA. If the data are skewed, the Wilxocon signed-rank test will be 
used in place of the paired t-test and the non-parametric ANOVA-type statistic will be 
used in place of the repeated measures ANOVA.8 
3.10 Timeline and Resources 
Resources from the CTNA, ARC, CMHC, Psychotherapy Development Research 
Center, and the Alcoholism Treatment Center at Yale will be utilized for this study. They 
will provide a trained clinician to administer the clinical diagnostic interview and medical 
screening, and trained staff to monitor subject recruitment, generate the randomization 
list, oversee self-reports and clinician-administered reports, and perform data analyses. 
The YNHH Investigational Pharmacy will prepare the experimental drugs, and a YNHH 
anesthesiologist will administer the intravenous solutions.  
The recruitment period will last 12 months. Participants will be enrolled until the 
target sample size of 56 individuals has been met. Upon enrollment, each participant will 
be randomized to one of the two treatment sequences. Participants will not need to wait 
until the target sample size is reached to achieve treatment since each participant will act 
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as his/her own control. The treatment period will last a total of ten weeks. The entire 
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Chapter 4 – Conclusion 
4.1 Strengths and Limitations 
There are multiple converging but preliminary lines of evidence that heighten our 
interest in testing psilocybin for AUD. In the last couple of decades researchers have built 
upon the foundational work of their predecessors with enhanced study designs that 
incorporate methods such as randomization, blinding, and a control-arm. Our study will 
be the second to examine, in a randomized, placebo-controlled, double-blind fashion, the 
efficacy of psilocybin on drinking outcomes in individuals with AUD. It will be a 
necessary step to advance to the next phase of clinical research: Phase 3 trials.  
One significant advantage of our study will be the use of ketamine as an active 
control for psilocybin. This sets our study apart from previous psilocybin (and other 
psychedelic) trials by incorporating another hallucinogen as the control condition. We 
expect that this will preserve the blind and in turn minimize expectancy bias and enhance 
validity. Despite evidence laid out in previous sections to the contrary, it is possible that 
ketamine will have a positive effect on drinking outcomes, which could confound our 
results. To address this, we have performed our sample size calculation accordingly, and 
estimated the effect of ketamine to be half the magnitude of the effect of psilocybin. 
Given the consistently large effect sizes detected for psilocybin in previous studies, we 
still expect to detect a statistically significant difference in effect between psilocybin and 
ketamine.  
Some advantages of this proposed study distinguish it from Bogenschutz’s RCT. 
First, the decision to include only hallucinogen-naïve individuals will help minimize 
expectancy bias on the part of participants, who will not necessarily be able to distinguish 
between the psychedelic drug effects due to lack of previous experience. Additionally, 
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this will prevent selection bias by avoiding recruiting individuals who previously had 
positive experiences with hallucinogens. The incorporation of a crossover design will 
reduce between-patient variation since subjects will act as their own controls, and will 
also allow for a smaller sample size, which will conserve study resources. A limitation of 
the crossover design is that it may lead to carryover and period effects. While we cannot 
be certain that the designated four-week washout period will be adequate, previous 
evidence supports that this length of time will be sufficient for any remaining acute drug 
effects to dissipate. We will further address these potential weaknesses by performing 
between- and within-group statistical analyses of the data. 
Additional limitations of this study include those inherent to psychedelic research 
in general, which were mentioned in Chapter 2. While these challenges are formidable, 
current research provides hope that they are surmountable.  
4.2 Clinical and Public Health Significance 
The potential advantages of a targeted intervention with psilocybin-assisted 
therapy for the treatment of AUD are numerous. Despite significant progress in 
alcoholism research over the past several decades, AUD remains a significant global 
health burden, in need of alternative treatment options with greater efficacy in a broader 
range of individuals.1,2 Current research indicates that psilocybin-assisted psychotherapy 
may be the answer. If this therapy were to be approved, it would offer a cheaper, faster 
alternative to current treatments, making it more accessible to a wider population. 
Adherence would be less of a concern: instead of chronic daily pills (and their associated 
costs and adverse effects), this therapy (if shown to be efficacious) would offer the 
promise of long-term beneficial effects from just a single drug-administration session. 
Additionally, unlike any single treatment today, this therapy addresses multiple domains 
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of addictive behavior, which the NIAAA has identified as necessary targets of future 
alcoholism research (i.e. craving, self-efficacy, motivation).3,4 Such an integrative 
approach could potentially treat a greater spectrum of the disease.   
In order to prove the clinical efficacy of these drugs, additional Phase 2 placebo-
controlled, double-blind, randomized controlled trials are needed to further demonstrate 
feasibility safety and efficacy. 
Bogenschutz predicts that “the therapeutic use of psychedelics in the treatment of 
addiction … will continue to increase in coming years, possibly leading to approved 
clinical uses for these medications.”5 While there is still a long road ahead before 
psilocybin potentially becomes an FDA-approved treatment of addiction, the very recent 
approval of esketamine (a ketamine derivative) for treatment-resistant depression 
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Appendix A: Concept Table 

























































































Appendix B: Sample size calculator 
 
 
*Note: we calculated sample size for a within-group comparison, yielding N = 52. After 





Appendix C: Table of inclusion and exclusion criteria 
Inclusion Criteria Exclusion Criteria 
➢ Desire to stop or decrease their 
drinking 
➢ Have at least two heavy drinking days 
in the past 30 days 
➢ Not participating in any formal 
treatment for alcohol dependence (12-
step meetings are not considered 
treatment) 
➢ English speaking- able to understand 
the process of consent and the risks 
and benefits associated with the 
study, and able to provide voluntary 
informed consent 
➢ Must sign a medical release for the 
investigators to communicate directly 
with their therapist and doctors to 
confirm a medication and/or 
medication history 
➢ Are willing to be driven home after 
the drug administration sessions by a 
driver arranged by the subject who 
will also stay overnight with the 
subject 
➢ Must provide a contact (relative, 
spouse, close friend, or other 
caregiver) who is willing and able to 
be reached by the Clinical 
Investigators in the event of a 
participant becoming suicidal. 
➢ If female of childbearing potential, 
are willing to use approved form of 
contraception from screening until 
after the psilocybin administration 
sessions 
➢ Able to provide adequate locator 
information 
➢ No prior history of hallucinogen use  
➢ The following medical conditions: 
seizure disorder, significantly impaired 
liver function, coronary artery disease, 
heart failure, uncontrolled 
hypertension (>165/95), history of 
cerebrovascular accident, asthma, 
hyperthyroidism, narrow-angle 
glaucoma, stenosing peptic ulcer, 
pyloroduodenal obstruction, 
symptomatic prostatic hypertrophy, 
bladder-neck obstruction. 
➢ The following psychiatric conditions: 
schizophrenia or other psychotic 
disorders, bipolar I or II disorder, 
current major depressive episode, 
current post-traumatic stress disorder, 
current suicidality or history of 
medically serious suicide attempt 
➢ Cognitive impairment (Folstein Mini 
Mental State Exam score <26) 
➢ Family history of schizophrenia, 
schizoaffective disorder (first- or 
second-degree relatives), or bipolar 
disorder type 1 (first degree relatives) 
➢ Cocaine, psychostimulant, opioid or 
cannabis dependence (past 12 months) 
➢ Current (past 30 days) or non-medical 
use of cocaine, psychostimulants (i.e. 
dextroamphetamine, 
methamphetamine, methylphenidate, 
ephedrine, phenylpropanolamine, and 
other anorectics and decongestants) or 
opioids. 
➢ Significant alcohol withdrawal 
(CIWA-Ar score >7. Patients 
presenting at screening in withdrawal 
may be referred for detoxification and 
reassessed within 30 days) 
➢ Serious ECG abnormalities (i.e. 
evidence of ischemia or MI) 
➢ Serious abnormalities of CBC or 
chemistries 
➢ Active legal problems with the 
potential to result in incarceration 
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➢ Pregnancy or lactation 
➢ Need to take the following 
medications: antidepressants, 
antipsychotics, psychostimulants, 
treatments for addictions, other 
dopaminergic or serotonergic agents, 
lithium, anticonvulsants) 
➢ High risk of adverse emotional or 
behavioral reaction based on 
investigator’s clinical evaluation (i.e. 
evidence of serious personality 
disorder, antisocial behavior, serious 






Appendix D: Informed consent form 
 
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
200 FR. 1 (2016-2)  
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL 
 
 
Study Title: Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder: A Double-
Blind Randomized Control Trial   
 
Principal Investigator: John Krystal, MD 
 
You are invited to participate in a research study designed to look at whether 
psychedelic-assisted treatment with psilocybin of alcohol use disorder (AUD) is clinically 
useful. Specifically, this study aims to: (1) characterize the acute effects of psilocybin in 
alcoholic patients (2) evaluate the effect of psilocybin treatment on drinking outcomes 
relative to a ketamine control. You are being asked to participate because you have been 
identified as someone who meets the eligibility requirements for our study. 
 
In order to decide whether or not you wish to be a part of this research study you 
should know enough about its risks and benefits to make an informed decision.  This 
consent form gives you detailed information about the research study, which a member of 
the research team will discuss with you.  This discussion should go over all aspects of this 
research: its purpose, the procedures that will be performed, any risks of the procedures, 
possible benefits and possible alternative treatments. Once you understand the study, you 
will be asked if you wish to participate; if so, you will be asked to sign this form. 
 




➢ Psilocybin and ketamine are classified as hallucinogens due to their ability to 
induce the following effects in humans: broad influences on consciousness and 
perception, including dissociation, distortions in visual, auditory, or somatosensory 
stimuli, or alterations in the perception of self or time, conceptual disorganization, 
hallucinations.  
➢ You will be randomly assigned to one of the two treatment sequences (both 
sequences receive identical treatments, just in a different order – i.e. AB/BA or 
BA/AB). The treatments you will receive will be both pharmacological and 
psychosocial in nature. 
➢ The pharmacological intervention will consist of two drug sessions. At each drug 
session both a pill and an intravenous treatment will be administered; the 
combination will always consist of an active treatment (moderate to high doses of 
either psilocybin or ketamine) paired with an inactive one (a placebo pill or IV 
saline solution); whichever combination you receive at the first session, you will 
receive the alternate at the second session, so that by the end of the trial you will 
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have received both ketamine and psilocybin. The purpose of creating to dosing 
sequences is to disguise which drug you will be getting at each session so as to 
preserve the integrity of the experiment.  
➢ The psychosocial treatment will consist seven sessions of motivational 
enhancement therapy, three preparation sessions, and two debriefing sessions. 
Content of therapy, preparation, and debriefing sessions may vary according to 
the participant’s needs; however, all sessions will follow the same standardized 
guidelines. These additional treatment components have been standardized in 
previous research, and are necessary components of psychedelic-assisted therapy 
to ensure your safety throughout the trial and maximize potential beneficial 
treatment effects. (See image below for outline of study visits). All study visits 
will take place at the Alcohol Treatment Center at Yale 
➢ Motivational enhancement therapy (MET) is a common intervention for the 
treatment of alcohol dependence. It consists of a patient-centered therapy that 
aims to produce rapid internally-motivated changes by exploring and resolving 
ambivalence towards behavior.  
➢ Preparation sessions will consist of a review of motivation and expectations for 
the study, detailed information about the physiological and psychological effects 
of the drugs, and advice on how to deal with potential dysphoric reactions to the 
drugs. At your first dosing session you will be oriented to the room in which the 
drug sessions will take place, shown the eye shades and headphones to be worn, 
and played a sample of the music to be played. 
➢ Debriefing sessions will occur on the following each drug administration session 
to allow you participant to reflect on his experience during the drug 
administration session. 
➢ During study visits you will be asked to complete questionnaires about your 
drinking behavior and aspects related to your drinking such as self-efficacy, 
craving, and motivation. The data from these questionnaires will be used to help 
us analyze the efficacy of the intervention.   
➢ Biological samples will be collected at an in-person screening visit in order to 
determine study eligibility (i.e. ECG, liver function tests, complete blood count, 
blood chemistries, urinalysis, and serum pregnancy test if female of child-bearing 
potential). Alcohol withdrawal will be assessed at a baseline visit and both drug 
administration sessions. Breath alcohol concentration will be collected at every 
visit in order to ensure your safe participation in the study.  
➢ All data collected as part of this study will remain confidential; it will not be 
included in your medical records nor will it be accessible to your medical 
providers.  
 
If you agree to participate in this study, you will be asked to attend all study visits 
outlined above. See figure below for further clarification. 
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as 
required by U.S. Law. This Web site will not include information that can identify you. 
At most, the Web site will include a summary of the results. You can search this Web site 
at any time. 
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You will be told of any significant new findings that are developed during the course of 
your participation in this study that may affect your willingness to continue to participate. 
 




Risks and Inconveniences 
 
Guidelines: 
➢ Ketamine and psilocybin have similar psychopharmacological effects. Lower 
doses of these drugs may induce a mild state of euphoria that is similar to that 
produced by a glass of wine, whereas higher subanesthetic doses (i.e. 0.5 mg/kg, 
IV over 40 minutes) produce alterations in sensory perception, feelings of 
unreality, and in some subjects mild psychosis.  These drugs have also been found 
to affect cognition (i.e. decrease mental sharpness, recall, and recognition) either 
during or shortly following administration. At doses perception-altering doses, 
these drugs may produce nausea and, in some cases, vomiting; this symptom may 
be managed by pretreatment with odansetron. In healthy subjects, these drugs 
typically produce a mild elevation in blood pressure and pulse rate that typically 
does not require medical intervention. Repeated ketamine administration appears 
to be safe when managed clinically. However, long-term heavy recreational use of 
ketamine, which can reach daily levels of 100-times the therapeutic dose, may lead 
to flashbacks, attentional, and other cognitive dysfunctions. Participation in this 
study may involve risks that are currently not known. 
 
➢ There is a federal law called the Genetic Information Nondiscrimination Act 
(GINA) that, in general, makes it illegal for health insurance companies, group 
health plans, and most employers, except those with fewer than 15 employees, to 
discriminate against you based on your genetic information.  However, it does not 
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protect you against discrimination by companies that sell life insurance, disability 
insurance, or long-term care insurance. 
 
Contrast Risks and Procedures Statements. 
Having an intravenous (IV) line placed is a very safe procedure.  There is a slight 
chance that multiple needle-sticks will be needed to make sure the IV is placed correctly.  
You might feel a small amount of pain when the IV is placed but it does not last very 
long.  A bruise or a minor infection might develop where the IV is placed.  A bruise will 
go away by itself and it might help if you wrap a warm towel around your arm.  
Infections can also be treated if necessary.      
You should tell your principal investigator: (1) if you are pregnant or breast 
feeding, (2) if you have a history of kidney disease, seizure, asthma, or allergic 






➢ There remains substantial room for the development of effective treatment 
alternatives for AUD and classic hallucinogens, particularly psilocybin, have 
shown promise in early studies. Recently completed proof-of-concept studies of 
psilocybin in conjunction with psychotherapy for nicotine and alcohol dependence 
demonstrated that the intervention led to substantial decreases in use of the target 
substance. Your participation in this study will help us to further understand the 
therapeutic role psilocybin for the treatment of AUD, with the possibility that in the 
future this treatment could become an approved alternative for many patients 
afflicted with this disease.  
➢ The proposed psilocybin intervention as a treatment for AUD is still under 
investigation and currently unproven, thus we cannot guarantee that you will 
benefit from this treatment. However, MET is an established treatment for AUD 






➢ You will be compensated for any costs involved in transporting to and from the 
study center. According to the rules of the Internal Revenue Service (IRS), 
payments that are made to you as a result of your participation in a study may be 
considered taxable income.  
➢ All costs associated with the medical screening visit (i.e. physical exam, laboratory 
tests) and all treatment interventions (drug sessions and therapy visits) will be 







Current treatment options for AUD consist of pharmacological interventions, behavioral 
therapy, and mutual support groups. The FDA has approved only three drugs for AUD:  
Naltrexone, Acamprosate, and Disulfiram, and these medications display poor efficacy, 
low adherence rates, or adverse effects at a population level.1 Empirically-validated 
behavioral interventions include cognitive behavioral therapy, motivational interviewing, 
and marital and family counseling. Mutual support treatment groups include Alcoholics 







Except as permitted by law, your health information will not be released in an identifiable 
form outside of the Yale University research team. Examples of information that we are 
legally required to disclose include abuse of a child or elderly person, or certain 
reportable diseases.  Note, however, that your records may be reviewed by those 
responsible for the proper conduct of research such as the Yale University Human 
Research Protection Program, Yale University Human Subjects Committee or 
representatives of the U.S. Department of Health and Human Services. The information 
about your health that will be collected in this study includes: 
➢ Baseline medical information (i.e. relevant current or past medical conditions, 
medication use, substance use) 
➢ History of alcohol use disorder (i.e. date of first diagnosis, previous treatments 
received) 
➢ Baseline biological data (i.e. blood tests, ECG) as mentioned above 
➢ Any personal material disclosed during therapy sessions  
Information may be re-disclosed if the recipients are not required by law to protect the 
privacy of the information.  At the conclusion of this study, any identifying information 
related to your research participation will be de-identified, rendering the data anonymous. 
Authorized representatives of the Food and Drug Administration (FDA) and the 
manufacturer of the drug being tested may need to review records of individual subjects.  
As a result, they may see your name; but they are bound by rules of confidentiality not to 




If you are injured while on study, seek treatment and contact the study doctor as soon as 
you are able.   
 
Yale School of Medicine, Yale-New Haven Hospital, and the Connecticut Mental Health 
Center do not provide funds for the treatment of research-related injury.  If you are injured 
as a result of your participation in this study, treatment will be provided.  You or your 
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insurance carrier will be expected to pay the costs of this treatment.  No additional financial 
compensation for injury or lost wages is available. 
 
You do not give up any of your legal rights by signing this form. 
 
Voluntary Participation and Withdrawal 
 
Guidelines: 
Participating in this study is voluntary. You are free to choose not to take part in this 
study.   Refusing to participate will involve no penalty or loss of benefits to which you 
are otherwise entitled (such as your health care outside the study, the payment for your 
health care, and your health care benefits).  However, you will not be able to enroll in this 
research study and will not receive study procedures as a study participant if you do not 
allow use of your information as part of this study. 
 
Withdrawing From the Study 
 
If you do become a subject, you are free to stop and withdraw from this study at any time 
during its course. To withdraw from the study, you can call a member of the research 
team at any time and tell them that you no longer want to take part.  This will cancel any 
future appointments. 
The researchers may withdraw you from participating in the research if necessary (i.e. if 
you are no longer compliant with exclusion/inclusion criteria of this study, or if you 
experience serious adverse side effects from the drug(s)). Withdrawing from the study will 
involve no penalty or loss of benefits to which you are otherwise entitled.  It will not harm 
your relationship with your own doctors or with New Haven Hospital or the Connecticut 
Mental Health Center. We would still, at your request, refer you to a clinic or doctor who 
can offer you treatment. 
 
When you withdraw from the study, no new health information identifying you will be 
gathered after that date.  Information that has already been gathered may still be used and 
given to others until the end of the research study, as necessary to insure the integrity of 




We have used some technical terms in this form.  Please feel free to ask about 
anything you don't understand and to consider this research and the consent form carefully 




I have read (or someone has read to me) this form and have decided to participate in the 
project described above.  Its general purposes, the particulars of my involvement and 
possible hazards and inconveniences have been explained to my satisfaction.  My signature 
















Signature of Principal Investigator  Date 
  
                                      or 
 
___________________________________________ ___________________ 
Signature of Person Obtaining Consent  Date 
 
 
If you have further questions about this project or if you have a research-related problem, 
you may contact the Principal Investigator John Krystal, MD. 
If, after you have signed this form you have any questions about your privacy rights, 
please contact the Yale Privacy Officer at 203-432-5919. If you would like to talk with 
someone other than the researchers to discuss problems, concerns, and questions you may 
have concerning this research, or to discuss your rights as a research subject, you may 
contact the Yale Human Investigation Committee at (203) 785-4688.  
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Appendix E: Verbal consent form 
Information Sheet 
Verbal Consent for Participation in a Research Study 
200 FR 9 (2017-2) 
 
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL 
 
Study Title: Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder: A Double-
Blind Randomized Control Trial   
 




You are being asked to join a research study.  The following information will explain the 
purpose of the study, what you will be asked to do, and the potential risks and benefits. 
You should ask questions before deciding whether you wish to participate, or at any time 




The purpose of this study is to further clarify whether psilocybin-assisted treatment of 
AUD is clinically useful.  You are being asked to participate because you have been 




If you choose to participate in the study, you will be asked to fully comply with the 
procedures of our study, which are described as follows: 
➢ You will be randomly assigned to one of the two treatment sequences (both 
sequences receive identical treatments, just in a different order – i.e. AB/BA, 
BA/AB) 
➢ Treatment will consist of two blinded drug administration sessions, seven 
sessions of motivational enhancement therapy, three preparation sessions, and 
two debriefing sessions. Content of therapy, preparation, and debriefing sessions 
may vary according to the participant’s needs, however, all sessions will follow 
the same standardized guidelines 
➢ Biological samples will be collected at an in-person screening visit in order to 
determine study eligibility (i.e. ECG, liver function tests, complete blood count, 
blood chemistries, urinalysis, and serum pregnancy test if female of child-bearing 
potential). Alcohol withdrawal will be assessed at a baseline visit and both drug 
administration sessions. Breath alcohol concentration will be collected at every 
visit in order to ensure your safe participation in the study.  
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➢ All data collected as part of this study will remain confidential; it will not be 





This research may or may not benefit you directly. However, knowledge gained from the 
results may help us to better understand the efficacy of psychedelic-assisted therapy for 




Your part in this research study consists solely of abiding to the protocol as specified 
above. This study does require you to have treatments, including the administration of 
drugs which are not currently approved for clinical use by the U.S. Food and Drug 
Administration. The potential exists for anticipated and/or unanticipated adverse events, 
serious or otherwise, to occur. Additionally, there is a slight risk regarding the 
confidentiality of your participation in this study, if information about you becomes 
known to persons outside this study.  The researchers are required to keep your study 
information confidential, however, so the risk of breach of confidentiality is very low. 
 
Alternatives to Participation 
 
Study staff will provide you will all information on alternative treatment options. Your 
participation in this study is voluntary. You are free to choose not to take part in this 
study at any time.  
 
Privacy / Confidentiality 
 
To protect your confidentiality, your name and other identifying information will not be 
recorded on any study documents. We will only collect information that is needed for 
research. Only the researchers involved in this study and those responsible for research 
oversight will have access to the information you provide.  
 
Research Authorization:  
 
Except as permitted by law, your health information will not be released in an identifiable 
form outside of the Yale University research team. Examples of information that we are 
legally required to disclose include abuse of a child or elderly person, or certain 
reportable diseases.  Note, however, that your records may be reviewed by those 
responsible for the proper conduct of research such as the Yale University Human 
Research Protection Program, Yale University Human Subjects Committee [or 
representatives of the U.S. Department of Health and Human Services or the name of 
research sponsor if applicable). The information about your health that will be collected 
in this study includes: 
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➢ Baseline medical information (i.e. relevant current or past medical conditions, 
medication use, substance use) 
➢ History of alcohol use disorder (i.e. date of first diagnosis, previous treatments 
received) 
➢ Baseline biological data (i.e. blood tests, ECG) as mentioned above 
➢ Any personal material disclosed during therapy sessions  
Information may be re-disclosed if the recipients are not required by law to protect the 
privacy of the information.  At the conclusion of this study, any identifying information 
related to your research participation will be de-identified, rendering the data anonymous. 
 
By agreeing to participate in this study, you authorize the use and/or disclosure of the 
information described above for this research study.  The purpose for the uses and 
disclosures you are authorizing is to ensure that the information relating to this research is 
available to all parties who may need it for research purposes. 
 
This authorization to use and disclose your health information collected during your 




Participation in this study is completely voluntary.  You are free to decline to participate, 
to end participation at any time for any reason, or to refuse to answer any individual 
question at any time.   Refusing to participate will involve no penalty or loss of benefits 
to which you are otherwise entitled (such as your health care outside the study, the 
payment for your health care, and your health care benefits). By providing verbal 
consent, you have not given up any of your legal rights. 
 
Questions 
You have heard the above description of the research study.  You have been told of the 
risks and benefits involved and, at this point, all of your questions regarding the study 
have been answered. 
 
 If you have any further questions about this study, you may contact the investigator, 
John Krystal, MD. If you would like to talk with someone other than the researchers to 
discuss problems, concerns, and questions you may have concerning this research, or to 
discuss your rights as a research subject, you may contact the Yale Human Investigation 




Appendix F: Data and safety monitoring plans form 




Greater Than Minimal Risk DSMP 
 
1. Personnel responsible for the safety review and its frequency: 
 
The principal investigator will be responsible for monitoring the data, assuring protocol 
compliance, and conducting the safety reviews at the specified frequency, which must be 
conducted at a minimum of every 6 months (including when reapproval of the protocol is 
sought).  During the review process, the principal investigator (monitor) will evaluate 
whether the study should continue unchanged, require modification/amendment, or close 
to enrollment. Either the principal investigator, the IRB or Yale Data and Safety 
Monitoring Committee (DSMC) have the authority to stop or suspend the study or 
require modifications. 
 
2. The risks associated with the current study are deemed greater than minimal for 
the following reasons:  
 
1. We do not view the risks associated with psilocybin and ketamine as minimal 
risks. 
2. Given the now established safety and validity of the current study drugs in our 
prior work, we do not view the proposed studies as high risk. 
 
Although we have assessed the proposed study as one of greater than minimal risk, the 
potential exists for anticipated and/or unanticipated adverse events, serious or otherwise, 
to occur since it is not possible to predict with certainty the absolute risk in any given 
individual or in advance of first-hand experience with the proposed study methods. 
Therefore, we provide a plan for monitoring the data and safety of the proposed study as 
follows: 
 
3. Attribution of Adverse Events: 
Adverse events will be monitored for each subject participating in the study and 
attributed to the study procedures / design by the principal investigator John Krystal, 
MD., according to the following categories: 
 
a.) Definite: Adverse event is clearly related to investigational procedures(s)/agent(s). 
b.) Probable: Adverse event is likely related to investigational procedures(s)/agent(s). 
c.) Possible: Adverse event may be related to investigational procedures(s)/agent(s). 
d.) Unlikely: Adverse event is likely not to be related to the investigational 
procedures(s)/agent(s). 




4. Plan for Grading Adverse Events: 
 
The following scale will be used in grading the severity of adverse events noted during 
the study: 
 
1. Mild adverse event 
2. Moderate adverse event 
3. Severe  
 
5. Plan for Determining Seriousness of Adverse Events: 
 
Serious Adverse Events: 
In addition to grading the adverse event, the PI will determine whether the adverse event 
meets the criteria for a Serious Adverse Event (SAE).  An adverse event is considered 
serious if it results in any of the following outcomes: 
 
1. Death; 
2. A life-threatening experience in-patient hospitalization or prolongation of 
existing hospitalization;  
3. A persistent or significant disability or incapacity;  
4. A congenital anomaly or birth defect; OR 
5. Any other adverse event that, based upon appropriate medical judgment, may 
jeopardize the subject’s health and may require medical or surgical intervention 
to prevent one of the other outcomes listed in this definition.  
 
An adverse event may be graded as severe but still not meet the criteria for a Serious 
Adverse Event.  Similarly, an adverse event may be graded as moderate but still meet the 
criteria for an SAE.  It is important for the PI to consider the grade of the event as well as 
its “seriousness” when determining whether reporting to the IRB is necessary. 
 
6. Plan for reporting UPIRSOs (including Adverse Events) to the IRB 
  
The principal investigator will report the following types of events to the IRB:  
Any incident, experience or outcome that meets ALL 3 of the following criteria: 
1. Is unexpected (in terms of nature, specificity, severity, or frequency) given (a) 
the research procedures described in the protocol-related documents, such as 
the IRB-approved protocol and informed consent document and (b) the 
characteristics of the subject population being studied; AND  
2. Is related or possibly related to participation in the research (possibly related 
means there is a reasonable possibility that the incident, experience, or 
outcome may have been caused by the procedures involved in the research); 
AND 
3. Suggests that the research places subjects or others at greater risk of harm 
(including physical, psychological, economic, legal, or social harm) than was 
previously known or recognized. 
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Unanticipated Problems Involving Risks to Subjects or Others (UPIRSOs) may be 
medical or non-medical in nature, and include – but are not limited to – serious, 
unexpected, and related adverse events and unanticipated adverse device effects.  
Please note that adverse events are reportable to the IRB as UPIRSOs only if they 
meet all 3 criteria listed above. 
 
These UPIRSOs/SAEs will be reported to the IRB in accordance with IRB Policy 710, 
using the appropriate forms found on the website. All related events involving risk but 
not meeting the prompt reporting requirements described in IRB Policy 710 should be 
reported to the IRB in summary form at the time of continuing review. If appropriate, 
such summary may be a simple brief statement that events have occurred at the expected 
frequency and level of severity as previously documented.  In lieu of a summary of 
external events, a current DSMB report can be submitted for research studies that are 
subject to oversight by a DSMB (or other monitoring entity that is monitoring the study 
on behalf of an industry sponsor). 
 
7. Plan for reporting adverse events to co-investigators on the study, as appropriate 
the protocol’s research monitor(s), e.g., industrial sponsor, Yale Cancer Center 
Data and Safety Monitoring Committee (DSMC), Protocol Review Committee 
(PRC), DSMBs, study sponsors, funding and regulatory agencies, and regulatory 
and decision-making bodies. 
 
For the current study, the following individuals, funding, and/or regulatory agencies will 
be notified: 
 
□ All Co-Investigators listed on the protocol. 
□ Food and Drug Administration  
□ Study Sponsor 
 
The principal investigator John Krystal, MD., will conduct a review of all adverse events 
upon completion of every study subject. The principal investigator will evaluate the 
frequency and severity of the adverse events and determine if modifications to the 
protocol or consent form are required. 
 
Please note: For any study that may be considered high risk, the IRB will be more 































 ADAI Sound Data Source—1/26/2007 {Project information} 
http://adai.washington.edu/sounddatasource  
Page 3  
ID #: _________________________ Date:  ___ ___ / ___ ___ / ___ ___ ___ ___ 
 
ALCOHOL ABSTINENCE SELF-EFFICACY (AASE) 
 
NEGATIVE AFFECT 
18 or 38.  When I am feeling angry inside 
16 or 36.  When I sense everything is going wrong for m e 
  3 or 23.  When I am feeling depressed 
14 or 34.  When I feel like blowing up because of frustration 
  6 or 26.  When I am very worried 
SOCIAL/POSITIVE 
15 or 35.  When I see others drinking at a bar or at a party 
20 or 40.  When I am excited or celebrating with others 
  4 or 24.  When I am on vacation and want to relax 
17 or 37.  When people I used to drink with encourage me to drink 
  8 or 28.  When I am being offered a drink in a social situation 
PHYSICAL AND OTHER CONCERNS 
  2 or 22.  When I have a headache 
12 or 32.  When I am physically tired 
  5 or 25.  When I am concerned about someone 
13 or 33.  When I am experiencing some physical pain or injury 
  9 or 29.  When I dream about taking a drink 
CRAVING AND URGES 
  1 or 21.  When I am in agony because of stopping or withdrawing from alcohol use 
  7 or 27.  When I have the urge to try just one drink to see what happens 
11 or 31.  When I am feeling a physical need or craving for alcohol 
10 or 30.  When I want to test my willpower over drinking 
19 or 39.  When I experience an urge or impulse to take a drink that catches me unprepared 
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Appendix J: Proposed protocol timeline for study visits and assessments 
 




1. A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence. 
National Library of Medicine (US); 2000 Feb 29. 
https://clinicaltrials.gov/ct2/show/NCT02061293. Accessed April 15 2019. 
2. A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence. 
National Library of Medicine (US); 2000 Feb 29. 
https://clinicaltrials.gov/ct2/show/NCT02061293. Accessed April 15 2019. 
3. The A.D.A.M. Medical Encyclopedia: Delirium Tremens. 2019. 
https://medlineplus.gov/encyclopedia.html. Accessed April 21, 2019 
4. Abramson HA. LSD in psychotherapy and alcoholism. American journal of 
psychotherapy. 1966;20(3):415-438. 
5. Abuzzahab FS, Sr., Anderson BJ. A review of LSD treatment in alcoholism. 
International pharmacopsychiatry. 1971;6(4):223-235. 
6. Akbar M, Egli M, Cho YE, Song BJ, Noronha A. Medications for alcohol use 
disorders: An overview. Pharmacology & therapeutics. 2018;185:64-85. 
7. Alcoholism NIoAAa. Alcohol Use Disorder.  https://www.niaaa.nih.gov/alcohol-
health/overview-alcohol-consumption/alcohol-use-disorders. Accessed March 25, 
2019. 
8. Alcoholism NIoAAa. Alcohol Use Disorder.  https://www.niaaa.nih.gov/alcohol-
health/overview-alcohol-consumption/alcohol-use-disorders. Accessed March 25, 
2019. 
9. Alcoholism NIoAAa. Expanding the Framework of Treatment. Alcohol Research 
& Health. 2010;33(4). 
10. Andersen K, Bogenschutz MP, Buhringer G, et al. Outpatient treatment of alcohol 
use disorders among subjects 60+ years: design of a randomized clinical trial 
conducted in three countries (Elderly Study). BMC psychiatry. 2015;15:280. 
11. Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine 
and phencyclidine, selectively reduce excitation of central mammalian neurones by 
N-methyl-aspartate. British journal of pharmacology. 1983;79(2):565-575. 
12. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and 
behavioral interventions for alcohol dependence: the COMBINE study: a 
randomized controlled trial. Jama. 2006;295(17):2003-2017. 
13. Association AP. Diagnostic and statistical manual of mental disorders (5th ed.). 
Arlington, VA: American Psychiatric Publishing; 2013. 
14. Barrett FS, Johnson MW, Griffiths RR. Validation of the revised Mystical 
Experience Questionnaire in experimental sessions with psilocybin. Journal of 
psychopharmacology (Oxford, England). 2015;29(11):1182-1190. 
15. Bas T.H. de Veen AFAS, Michel M.M. Verheij & Judith R. Homberg. Psilocybin 
for treating substance use disorders? Expert review of neurotherapeutics. 
2017;17(2):203-212. 
16. Berger L, Fisher M, Brondino M, et al. Efficacy of acamprosate for alcohol 
dependence in a family medicine setting in the United States: a randomized, 
double-blind, placebo-controlled study. Alcoholism, clinical and experimental 
research. 2013;37(4):668-674. 
 27 
17. Blanco-Gandia MC, Rodriguez-Arias M. Pharmacological treatments for opiate 
and alcohol addiction: A historical perspective of the last 50 years. European 
journal of pharmacology. 2018;836:89-101. 
18. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman 
RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. 
Journal of psychopharmacology (Oxford, England). 2015;29(3):289-299. 
19. Bogenschutz MP, Forcehimes, A. A. Development of a Psychotherapeutic Model 
for Psilocybin-Assisted Treatment of Alcoholism. Journal of Humanistic 
Psychology. 2017;57(4):389-414. 
20. Bogenschutz MP, Johnson MW. Classic hallucinogens in the treatment of 
addictions. Progress in neuro-psychopharmacology & biological psychiatry. 
2016;64:250-258. 
21. Bogenschutz MP, Johnson MW. Classic hallucinogens in the treatment of 
addictions. Progress in neuro-psychopharmacology & biological psychiatry. 
2016;64:250-258. 
22. Bogenschutz MP, Pommy JM. Therapeutic mechanisms of classic hallucinogens in 
the treatment of addictions: from indirect evidence to testable hypotheses. Drug 
testing and analysis. 2012;4(7-8):543-555. 
23. Bogenschutz MP, Pommy JM. Therapeutic mechanisms of classic hallucinogens in 
the treatment of addictions: from indirect evidence to testable hypotheses. Drug 
testing and analysis. 2012;4(7-8):543-555. 
24. Bogenschutz MP, Ross S. Therapeutic Applications of Classic Hallucinogens. 
Current topics in behavioral neurosciences. 2018;36:361-391. 
25. Bogenschutz MP. Studying the effects of classic hallucinogens in the treatment of 
alcoholism: rationale, methodology, and current research with psilocybin. Current 
drug abuse reviews. 2013;6(1):17-29. 
26. Bogenschutz MP. Studying the effects of classic hallucinogens in the treatment of 
alcoholism: rationale, methodology, and current research with psilocybin. Current 
drug abuse reviews. 2013;6(1):17-29. 
27. Boothby LA, Doering PL. Acamprosate for the treatment of alcohol dependence. 
Clinical therapeutics. 2005;27(6):695-714. 
28. Bouchery EE, Harwood HJ, Sacks JJ, Simon CJ, Brewer RD. Economic costs of 
excessive alcohol consumption in the U.S., 2006. American journal of preventive 
medicine. 2011;41(5):516-524. 
29. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological 
support for treatment-resistant depression: an open-label feasibility study. The 
lancet. Psychiatry. 2016;3(7):619-627. 
30. Carhart-Harris RL, Williams TM, Sessa B, et al. The administration of psilocybin 
to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic 
resonance imaging environment: a preliminary investigation of tolerability. Journal 
of psychopharmacology (Oxford, England). 2011;25(11):1562-1567. 
31. Cavicchioli M, Movalli M, Maffei C. The Clinical Efficacy of Mindfulness-Based 
Treatments for Alcohol and Drugs Use Disorders: A Meta-Analytic Review of 
Randomized and Nonrandomized Controlled Trials. Eur Addict Res. 
2018;24(3):137-162. 
 28 
32. Cheng WJ, Chen CH, Chen CK, et al. Similar psychotic and cognitive profile 
between ketamine dependence with persistent psychosis and schizophrenia. 
Schizophrenia research. 2018;199:313-318. 
33. De Gregorio D, Enns JP, Nunez NA, Posa L, Gobbi G. d-Lysergic acid 
diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and 
potential therapeutic applications in mood disorders. Progress in brain research. 
2018;242:69-96. 
34. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-
methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Archives 
of general psychiatry. 2010;67(8):793-802. 
35. Dittrich A. The standardized psychometric assessment of altered states of 
consciousness (ASCs) in humans. Pharmacopsychiatry. 1998;31 Suppl 2:80-84. 
36. Doblin R. Regulation of the Medical Use of Psychedeilcs and Marijuana 
[Dissertation]: Kennedy School of Government, Harvard University; 2001. 
37. Dos Santos RG, Osorio FL, Crippa JA, Riba J, Zuardi AW, Hallak JE. 
Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and 
lysergic acid diethylamide (LSD): a systematic review of clinical trials published in 
the last 25 years. Therapeutic advances in psychopharmacology. 2016;6(3):193-
213. 
38. Dos Santos RG, Osorio FL, Crippa JA, Riba J, Zuardi AW, Hallak JE. 
Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and 
lysergic acid diethylamide (LSD): a systematic review of clinical trials published in 
the last 25 years. Therapeutic advances in psychopharmacology. 2016;6(3):193-
213. 
39. Elias D, Kleber HD. Minding the brain: the role of pharmacotherapy in substance-
use disorder treatment. Dialogues in clinical neuroscience. 2017;19(3):289-297. 
40. Evans SM, Levin FR, Brooks DJ, Garawi F. A pilot double-blind treatment trial of 
memantine for alcohol dependence. Alcoholism, clinical and experimental 
research. 2007;31(5):775-782. 
41. Falk DE, Litten RZ, Anton RF, Kranzler HR, Johnson BA. Cumulative proportion 
of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol 
clinical trials. Journal of studies on alcohol and drugs. 2014;75(2):335-346. 
42. Fertig JB, Ryan ML, Falk DE, et al. A double-blind, placebo-controlled trial 
assessing the efficacy of levetiracetam extended-release in very heavy drinking 
alcohol-dependent patients. Alcoholism, clinical and experimental research. 
2012;36(8):1421-1430. 
43. First MB WJ, Karg RS, Spitzer RL. Structured Clinical Interview for DSM-5, 
Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV. Arlington, 
VA: American Psychiatric Association; 2015. 
44. First MB WJ, Karg RS, Spitzer RL. Structured Clinical Interview for DSM-5, 
Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV. Arlington, 
VA: American Psychiatric Association; 2015. 
45. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism. 
A Veterans Administration cooperative study. Jama. 1986;256(11):1449-1455. 
 29 
46. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-
acting injectable naltrexone for alcohol dependence: a randomized controlled trial. 
Jama. 2005;293(13):1617-1625. 
47. Garcia-Romeu A, Richards WA. Current perspectives on psychedelic therapy: use 
of serotonergic hallucinogens in clinical interventions. International review of 
psychiatry (Abingdon, England). 2018:1-26. 
48. Griffiths R, Richards W, Johnson M, McCann U, Jesse R. Mystical-type 
experiences occasioned by psilocybin mediate the attribution of personal meaning 
and spiritual significance 14 months later. Journal of psychopharmacology (Oxford, 
England). 2008;22(6):621-632. 
49. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial 
and sustained decreases in depression and anxiety in patients with life-threatening 
cancer: A randomized double-blind trial. Journal of psychopharmacology (Oxford, 
England). 2016;30(12):1181-1197. 
50. Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin-occasioned mystical-
type experience in combination with meditation and other spiritual practices 
produces enduring positive changes in psychological functioning and in trait 
measures of prosocial attitudes and behaviors. Journal of psychopharmacology 
(Oxford, England). 2018;32(1):49-69. 
51. Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. 
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-
related effects. Psychopharmacology. 2011;218(4):649-665. 
52. Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-
type experiences having substantial and sustained personal meaning and spiritual 
significance. Psychopharmacology. 2006;187(3):268-283; discussion 284-292. 
53. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for 
anxiety in patients with advanced-stage cancer. Archives of general psychiatry. 
2011;68(1):71-78. 
54. Grob CS. Psychiatric research with hallucinogens: what have we learned. In: David 
E. Nichols PD, ed. The Heffter Review of Psychedelic Research. Vol 1. Santa Fe, 
NM: The Heffter Research Institute; 1998:8-20. 
55. Gueorguieva R, Wu R, Donovan D, et al. Naltrexone and combined behavioral 
intervention effects on trajectories of drinking in the COMBINE study. Drug and 
alcohol dependence. 2010;107(2-3):221-229. 
56. Gueorguieva R, Wu R, Pittman B, et al. New insights into the efficacy of 
naltrexone based on trajectory-based reanalyses of two negative clinical trials. 
Biological psychiatry. 2007;61(11):1290-1295. 
57. Hammond FM, J; Nick, T. G.; Buschbacher, R. Handbook for Clinical Research : 
Design, Statistics, and Implementation. Demos Medical Publishing; 2014: 
https://ebookcentral.proquest.com/lib/yale-ebooks/detail.action?docID=3007787. 
58. Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological 
and physiological effects of psilocybin in healthy humans: a double-blind, placebo-
controlled dose-effect study. Psychopharmacology. 2004;172(2):145-156. 
59. Hollister LE, Shelton J, Krieger G. A controlled comparison of lysergic acid 
diethylamide (LSD) and dextroamphetmine in alcoholics. The American journal of 
psychiatry. 1969;125(10):1352-1357. 
 30 
60. Institute U. Investigator’s Brochure: Psilocybin.  07 February 2018 2018. 
61. Jansen KL. A review of the nonmedical use of ketamine: use, users and 
consequences. Journal of psychoactive drugs. 2000;32(4):419-433. 
62. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol 
dependence: a randomized controlled trial. Jama. 2007;298(14):1641-1651. 
63. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for 
safety. Journal of psychopharmacology (Oxford, England). 2008;22(6):603-620. 
64. Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-
HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of 
psychopharmacology (Oxford, England). 2014;28(11):983-992. 
65. Jones JL, Mateus CF, Malcolm RJ, Brady KT, Back SE. Efficacy of Ketamine in 
the Treatment of Substance Use Disorders: A Systematic Review. Frontiers in 
psychiatry. 2018;9:277. 
66. Kaner EF, Beyer FR, Muirhead C, et al. Effectiveness of brief alcohol interventions 
in primary care populations. The Cochrane database of systematic reviews. 
2018;2:Cd004148. 
67. Kaskutas LA. Alcoholics anonymous effectiveness: faith meets science. Journal of 
addictive diseases. 2009;28(2):145-157. 
68. Kaskutas LAT, N.; Bond, J.; Weisner, C. The role of religion, spirituality and 
Alcoholics Anonymous in sustained sobriety. Alcoholism Treatment Quarterly. 
2003;21(1):1-16. 
69. Kometer M, Schmidt A, Jancke L, Vollenweider FX. Activation of serotonin 2A 
receptors underlies the psilocybin-induced effects on alpha oscillations, N170 
visual-evoked potentials, and visual hallucinations. The Journal of neuroscience : 
the official journal of the Society for Neuroscience. 2013;33(25):10544-10551. 
70. Konietschke FB, A.C.; Hothorn, L.A.; Brunner, E. Testing and estimation of purely 
nonparametric effects in repeated measures designs. Computational Statistics & 
Data Analysis. 2010;54(8):1895-1905. 
71. Kranzler HR, Wetherill R, Feinn R, Pond T, Gelernter J, Covault J. Posttreatment 
effects of topiramate treatment for heavy drinking. Alcoholism, clinical and 
experimental research. 2014;38(12):3017-3023. 
72. Krebs TS, Johansen PO. Lysergic acid diethylamide (LSD) for alcoholism: meta-
analysis of randomized controlled trials. Journal of psychopharmacology (Oxford, 
England). 2012;26(7):994-1002. 
73. Krupitsky EM, Grinenko AY. Ketamine psychedelic therapy (KPT): a review of 
the results of ten years of research. Journal of psychoactive drugs. 1997;29(2):165-
183. 
74. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive 
NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, 
and neuroendocrine responses. Archives of general psychiatry. 1994;51(3):199-
214. 
75. Krystal JH, Petrakis IL, Webb E, et al. Dose-related ethanol-like effects of the 
NMDA antagonist, ketamine, in recently detoxified alcoholics. Archives of general 
psychiatry. 1998;55(4):354-360. 
76. Litten RZ, Falk DE, Ryan ML, Fertig JB. Discovery, Development, and Adoption 
of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications 
 31 
Development. Alcoholism, clinical and experimental research. 2016;40(7):1368-
1379. 
77. Litten RZ, Fertig JB, Falk DE, et al. A double-blind, placebo-controlled trial to 
assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-
dependent patients. Alcoholism, clinical and experimental research. 
2012;36(3):406-416. 
78. Litten RZ, Wilford BB, Falk DE, Ryan ML, Fertig JB. Potential medications for 
the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety. 
Substance abuse. 2016;37(2):286-298. 
79. Loo CK, Galvez V, O'Keefe E, et al. Placebo-controlled pilot trial testing dose 
titration and intravenous, intramuscular and subcutaneous routes for ketamine in 
depression. Acta psychiatrica Scandinavica. 2016;134(1):48-56. 
80. Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis 
of naltrexone and acamprosate for treating alcohol use disorders: when are these 
medications most helpful? Addiction (Abingdon, England). 2013;108(2):275-293. 
81. Mangini M. Treatment of alcoholism using psychedelic drugs: a review of the 
program of research. Journal of psychoactive drugs. 1998;30(4):381-418. 
82. Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on 
abstinence in patients with alcohol dependence in a double-blind, placebo-
controlled trial: the role of patient motivation. Journal of psychiatric research. 
2006;40(5):383-393. 
83. Mason BJ. Acamprosate in the treatment of alcohol dependence. Expert opinion on 
pharmacotherapy. 2005;6(12):2103-2115. 
84. Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH 
posttreatment drinking outcomes. Journal of studies on alcohol. 1997;58(1):7-29. 
85. McAndrew A, Lawn W, Stevens T, Porffy L, Brandner B, Morgan CJ. A proof-of-
concept investigation into ketamine as a pharmacological treatment for alcohol 
dependence: study protocol for a randomised controlled trial. Trials. 
2017;18(1):159. 
86. Metzner R. Sacred Mushroom of Visions: Teonanácatl: A Sourcebook on the 




87. Miller WR, Zweben, A., DiClemente, C. C., Rychtarik, R. G. Motivational 
Enhancement Therapy Manual: A Clinical Research Guide for Therapists Treating 
Individuals With Alcohol Abuse and Dependence. In: Alcoholism NIoAAa, ed. Vol 
21999. 
88. Mills EJ, Chan AW, Wu P, Vail A, Guyatt GH, Altman DG. Design, analysis, and 
presentation of crossover trials. Trials. 2009;10:27. 
89. Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and 
efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. The 
Journal of clinical psychiatry. 2006;67(11):1735-1740. 
90. Moyers TB, Martin T, Manuel JK, Hendrickson SM, Miller WR. Assessing 
competence in the use of motivational interviewing. Journal of substance abuse 
treatment. 2005;28(1):19-26. 
 32 
91. National Collaborating Centre for Mental H. National Institute for Health and 
Clinical Excellence: Guidance. Alcohol-Use Disorders: Diagnosis, Assessment and 
Management of Harmful Drinking and Alcohol Dependence. Leicester (UK): 
British Psychological Society, The British Psychological Society & The Royal 
College of Psychiatrists.; 2011. 
92. Nielson EMM, D. G.; Forcehimes, A. A.; Bogenschutz, M. P. The Psychedelic 
Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena 
through Qualitative Content Analysis of Clinical Sessions. Frontiers in 
pharmacology. 2018;9(132). 
93. Nutt D. Psilocybin for anxiety and depression in cancer care? Lessons from the past 
and prospects for the future. Journal of psychopharmacology (Oxford, England). 
2016;30(12):1163-1164. 
94. O'Malley SS, Corbin WR, Leeman RF, et al. Reduction of alcohol drinking in 
young adults by naltrexone: a double-blind, placebo-controlled, randomized 
clinical trial of efficacy and safety. The Journal of clinical psychiatry. 
2015;76(2):e207-213. 
95. O’Brien CP, Jones R. T. Methodological issues in the evaluation of a medication 
for its potential benefits in enhancing therapy. 50 years of LSD: Current Status and 





Accessed March 26, 2019. 
96. Organization WH. Global status report on alcohol and health. 2014. 
97. Preller KH, Burt JB, Ji JL, et al. Changes in global and thalamic brain connectivity 
in LSD-induced altered states of consciousness are attributable to the 5-HT2A 
receptor. eLife. 2018;7. 
98. Preller KH, Herdener M, Pokorny T, et al. The Fabric of Meaning and Subjective 
Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation. 
Current biology : CB. 2017;27(3):451-457. 
99. Preller KH, Pokorny T, Hock A, et al. Effects of serotonin 2A/1A receptor 
stimulation on social exclusion processing. Proceedings of the National Academy 
of Sciences of the United States of America. 2016;113(18):5119-5124. 
100. Programme WMHGA. Psychosocial interventions for the management of alcohol 
dependence. World Health Organization;2015. 
101. Rasmussen KG, Lineberry TW, Galardy CW, et al. Serial infusions of low-dose 
ketamine for major depression. Journal of psychopharmacology (Oxford, England). 
2013;27(5):444-450. 
102. Ray LA, Bujarski S, Roche DJO, Magill M. Overcoming the "Valley of Death" in 
Medications Development for Alcohol Use Disorder. Alcoholism, clinical and 
experimental research. 2018;42(9):1612-1622. 
103. Rohsenow DJP-C, M. M. Cognitive-Behavioral Approaches. In: Sher KJ, ed. The 
Oxford Handbook of Substance Use and Substance Use DIsorders: Volume 2: 
Oxford University Press; 2016. 
 33 
104. Roseman L, Nutt DJ, Carhart-Harris RL. Quality of Acute Psychedelic Experience 
Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. 
Frontiers in pharmacology. 2017;8:974. 
105. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following 
psilocybin treatment for anxiety and depression in patients with life-threatening 
cancer: a randomized controlled trial. Journal of psychopharmacology (Oxford, 
England). 2016;30(12):1165-1180. 
106. Rucker JJH, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & 
future. Neuropharmacology. 2018;142:200-218. 
107. Salib AN, Ho AL, Sussman ES, Pendharkar AV, Halpern CH. Neuromodulatory 
Treatments for Alcohol Use Disorder: A Review. Brain sciences. 2018;8(6). 
108. Savage C, McCabe OL. Residential psychedelic (LSD) therapy for the narcotic 
addict. A controlled study. Archives of general psychiatry. 1973;28(6):808-814. 
109. Sellers EM, Leiderman DB. Psychedelic Drugs as Therapeutics: No Illusions 
About the Challenges. Clinical pharmacology and therapeutics. 2018;103(4):561-
564. 
110. Shram MJ, Sellers EM, Romach MK. Oral ketamine as a positive control in human 
abuse potential studies. Drug and alcohol dependence. 2011;114(2-3):185-193. 
111. Siegel RK. Phencyclidine and ketamine intoxication: a study of four populations of 
recreational users. NIDA research monograph. 1978(21):119-147. 
112. Skinner MD, Lahmek P, Pham H, Aubin HJ. Disulfiram efficacy in the treatment of 
alcohol dependence: a meta-analysis. PloS one. 2014;9(2):e87366. 
113. Sobell LC, Sobell MB, Connors GJ, Agrawal S. Assessing drinking outcomes in 
alcohol treatment efficacy studies: selecting a yardstick of success. Alcoholism, 
clinical and experimental research. 2003;27(10):1661-1666. 
114. Sobell LCS, M. B. Alcohol Consumption Measures. In: Allen JPW, V. B., ed. 
Assessing Alcohol Problems: A Guide for Clinicians and Researchers, 2nd Edition: 
National Institutes of Health; 2004. 
115. Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-
term subjective effects of psilocybin in healthy humans: a pooled analysis of 
experimental studies. Journal of psychopharmacology (Oxford, England). 
2011;25(11):1434-1452. 
116. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of 
alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol 
scale (CIWA-Ar). British journal of addiction. 1989;84(11):1353-1357. 
117. Swift R. Pharmacotherapy of Substance Use, Craving, and Acute Abstinence 
Syndromes. In: Sher KJ, ed. The Oxford Handbook of Sustance Use and Substance 
Use DIsorders: Volume 2: Oxford University Press; 2015. 
118. Tonigan JS. Applied Issues in Treatment Outcome Assessment. In: Allen JPW, V. 
B., ed. Assessing Alcohol Problems:  A Guide for Clinicians and Researchers, 2nd 
Ed.: National Institutes of Health; 2004. 
119. use CfMPfH. Guideline on the development of medicinal products for the treatment 
of alcohol dependence. European Medicines Agency;2010. 
120. Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: 
implications for the treatment of mood disorders. Nature reviews. Neuroscience. 
2010;11(9):642-651. 
 34 
121. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D. 
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 
agonist action. Neuroreport. 1998;9(17):3897-3902. 
122. Wilson AD, Bravo AJ, Pearson MR, Witkiewitz K. Finding success in failure: 
using latent profile analysis to examine heterogeneity in psychosocial functioning 
among heavy drinkers following treatment. Addiction (Abingdon, England). 
2016;111(12):2145-2154. 
123. Witkiewitz K, Wilson AD, Pearson MR, et al. Temporal Stability of Heavy 
Drinking Days and Drinking Reductions Among Heavy Drinkers in the COMBINE 
Study. Alcoholism, clinical and experimental research. 2017;41(5):1054-1062. 
124. Zanos P, Moaddel R, Morris PJ, et al. Ketamine and Ketamine Metabolite 
Pharmacology: Insights into Therapeutic Mechanisms. Pharmacological reviews. 
2018;70(3):621-660. 
125. Zarate CA, Jr., Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-
aspartate antagonist in treatment-resistant major depression. Archives of general 
psychiatry. 2006;63(8):856-864. 
126. Zemore SE, Lui C, Mericle A, Hemberg J, Kaskutas LA. A longitudinal study of 
the comparative efficacy of Women for Sobriety, LifeRing, SMART Recovery, and 
12-step groups for those with AUD. Journal of substance abuse treatment. 
2018;88:18-26. 
127. Zemore SE. A role for spiritual change in the benefits of 12-step involvement. 
Alcoholism, clinical and experimental research. 2007;31(10 Suppl):76s-79s. 
128. Zinberg NE. Drug, Set, and Setting: The Basis for Controlled Intoxicant Use. Yale 
University Press; 1986. 
 
 
 
 
